image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
3714382913748d8ea88821b07694f647a8cff42119a58c1304c25779d78fff4a.png | simple | <table><tr><td>International source</td><td>Range of time requirement in minutes</td><td>Average time requirement in minutes</td></tr><tr><td>ECDC Round Table Report</td><td>< 15–60</td><td>40</td></tr><tr><td>ProMED-mail</td><td>< 15–45</td><td>35</td></tr><tr><td>WHO Event Information Site (EIS)</td><td>< 15–30</td><td>25</td></tr><tr><td>EPIS for Food- and Waterborne Diseases and Zoonoses (EPIS-FWD)</td><td>< 15–30</td><td>15</td></tr><tr><td>WHO Disease Outbreak News (DON)</td><td>< 15–30</td><td>20</td></tr><tr><td>European Early Warning and Response System (EWRS)</td><td>< 15–40</td><td>30</td></tr><tr><td><i>Eurosurveillance</i></td><td>< 15–30</td><td>25</td></tr><tr><td>Emerging Infections (EI) Summary</td><td>< 15–45</td><td>20</td></tr><tr><td>Morbidity and Mortality Weekly Report (MMWR)</td><td>< 15</td><td>10</td></tr><tr><td>WHO Weekly Epidemiological Records (WER)</td><td>< 15</td><td>10</td></tr><tr><td>TOTAL</td><td>150–330</td><td>230</td></tr></table> |
193f0d8965386c37de081d2193fcfbf1d5427efb9bf7c98aa56f55e9bf58cf77.png | simple | <table><tr><td>Agent</td><td>Specific mechanism</td><td>Highest level of studies</td><td>Result</td></tr><tr><td>Tauroursodeoxycholic acid</td><td>Chemical chaperone</td><td>Randomized controlled trials</td><td>Improved insulin sensitivity in muscle and liver in obese individuals [86]</td></tr><tr><td>Phenylbutyrate</td><td>Chemical chaperone</td><td>Randomized controlled trials</td><td>Improved insulin sensitivity and beta-cell function in lipid-infused individuals [87]</td></tr><tr><td>Azoramide</td><td>ATF6 activators</td><td>Rodents</td><td>Improves insulin sensitivity and beta-cell function in obese mice [89]</td></tr><tr><td>Valproate</td><td>Increasing GRPP78</td><td>Rodents</td><td>Ameliorates atherosclerosis and hepatic steatosis in <i>Apoe</i><sup>−/−</sup>mice [90]</td></tr><tr><td>L-Carnitine or carnitine-orotate</td><td>Fatty acid transfer for beta-oxidation</td><td>Randomized controlled trials</td><td>Twelve of 17 studies showing improved insulin sensitivity or glycemic control in type 2 diabetic patients or alleviation of hepatic steatosis [98, 99]</td></tr><tr><td>Co-enzyme Q<sub>10</sub></td><td>Electron carrier from complex I and II to complex III</td><td>Randomized controlled trials</td><td>No net effect on glycemic control in type 2 diabetic patients [100]</td></tr><tr><td><i>α</i>-lipoic acid</td><td>Antioxidant</td><td>Randomized controlled trials; rodent</td><td>Weight-reducing, glucose-lowering, and insulin-sensitizing effect; prevention of hepatic steatosis [101–110]</td></tr><tr><td>Vitamin E</td><td>Antioxidant</td><td>Randomized controlled trials</td><td>Inconsistent results on glycemic control [111–115]; reduced hepatic steatosis [122]</td></tr><tr><td><i>N</i>-acetylcysteine</td><td>Antioxidant</td><td>Rodents</td><td>Prevents diet-induced obesity [116–118]</td></tr><tr><td>Peptide SS31</td><td>Mitochondria-targeted antioxidant peptide</td><td>Rodent</td><td>Improved glucose tolerance in diet-induced obese mice [38]</td></tr><tr><td>Resveratrol</td><td>SIRT1 agonist</td><td>Randomized controlled trials</td><td>Improved insulin sensitivity and glycemic control in diabetic patients; no effect in nondiabetic patients [120];</td></tr><tr><td>GSK5182</td><td>Estrogen-related receptor gamma inverse agonist</td><td>Rodents</td><td>Reduces hyperglycemia due to inhibition of hepatic gluconeogenesis [121]</td></tr><tr><td>Trehalose, imanitib</td><td>Enhance autophagy</td><td>Rodents</td><td>Improved glucose tolerance and insulin sensitivity in obese mice [84]</td></tr><tr><td>Dh404</td><td>Nrf2 activator</td><td>Rodents</td><td>Increased viability of islet by enhancing autophagy [123]</td></tr></table> |
9fa195cab3b7a4379d25c9cb0e2276539a4c8e27ca359914e4c6b4b06c5c97fe.png | complex | <table><tr><td>Factor</td><td>Parameter Estimate (95% CI)</td><td><i>P</i></td></tr><tr><td colspan="3">Mean arterial blood pressure</td></tr><tr><td> Smoker</td><td>3.49 (−2.67, 9.64)</td><td>.257</td></tr><tr><td> Male sex</td><td>−38.45 (−91.78 to 14.88)</td><td>.151</td></tr><tr><td> Age</td><td>0.25 (−.14 to .64)</td><td>.202</td></tr><tr><td> Body mass index</td><td>0.19 (−.61 to .99)</td><td>.625</td></tr><tr><td> Antihypertensive</td><td>1.44 (5.19–8.06)</td><td>.662</td></tr><tr><td> CD4<sup>+</sup> iTreg count,<sup>a</sup> per 10-fold increase</td><td>20.72 (7.03–34.41)</td><td>.004</td></tr><tr><td> Sex-associated CD4<sup>+</sup> iTreg frequency<sup>b</sup></td><td>−18.40 (−41.80 to 4.99)</td><td>.119</td></tr><tr><td colspan="3">Diastolic blood pressure</td></tr><tr><td> Smoker</td><td>3.09 (−3.54 to 9.72)</td><td>.349</td></tr><tr><td>Male sex</td><td>−62.14 (−119.59 to −4.70)</td><td>.035</td></tr><tr><td> Age</td><td>−0.04 (−.45 to .38)</td><td>.858</td></tr><tr><td> Body mass index</td><td>0.44 (−.42 to 1.30)</td><td>.301</td></tr><tr><td> Antihypertensive</td><td>1.86 (−5.28 to 8.99)</td><td>.600</td></tr><tr><td> CD4<sup>+</sup> iTreg count, per 10-fold increase</td><td>21.50 (6.75–36.25)</td><td>.006</td></tr><tr><td> Sex-associated CD4<sup>+</sup> iTreg frequency<sup>a,b</sup></td><td>−28.07 (−53.27 to −2.87)</td><td>.030</td></tr></table> |
95561406731589159c1934921b1caee32715761e2f3803c4b9af45707ae0a466.png | complex | <table><tr><td rowspan="2">Parameter</td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td>HR(95% CI)</td><td>P-value</td><td>HR (95% CI)</td><td>P-value</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td></tr><tr><td>Female</td><td>1(Referent)</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>3.272 (1.781-6.01)</td><td>0.091</td><td></td><td></td></tr><tr><td>Histology</td><td></td><td></td><td></td><td></td></tr><tr><td>WHO Type 2</td><td>1(Referent)</td><td></td><td></td><td></td></tr><tr><td>WHO Type 3</td><td>0.813(0.539-1.227)</td><td>0.324</td><td></td><td></td></tr><tr><td>Age at diagnosis (years)</td><td></td><td></td><td></td><td></td></tr><tr><td><50</td><td>1(Referent)</td><td></td><td></td><td></td></tr><tr><td>≥50</td><td>1.154(0.751-1.773)</td><td>0.513</td><td></td><td></td></tr><tr><td>Tumor classification</td><td></td><td></td><td></td><td></td></tr><tr><td>T1+2</td><td>1(Referent)</td><td></td><td></td><td></td></tr><tr><td>T3+4</td><td>2.876(1.814-4.558)</td><td><0.001</td><td>1.847 (1.106-3.084)</td><td>0.019</td></tr><tr><td>Lymph node classification</td><td></td><td></td><td></td><td></td></tr><tr><td>N0+1</td><td>1(Referent)</td><td></td><td></td><td></td></tr><tr><td>N2+3</td><td>2.550(1.644-3.953)</td><td><0.001</td><td>1.827 (1.126-2.966)</td><td>0.015</td></tr><tr><td>TNM stage(AJCC)</td><td></td><td></td><td></td><td></td></tr><tr><td>I+II</td><td>1(Referent)</td><td></td><td></td><td></td></tr><tr><td>III+IV</td><td>11.791(3.728-37.225)</td><td><0.001</td><td>4.757(1.316-17.201)</td><td>0.017</td></tr><tr><td>GGT</td><td></td><td></td><td></td><td></td></tr><tr><td><23</td><td>1(Referent)</td><td></td><td></td><td></td></tr><tr><td>≥23</td><td>3.465 (2.174-5.523)</td><td><0.001</td><td>3.119 (1.955-4.976)</td><td>0.031</td></tr></table> |
2d5bed8c96e87abe7b35e4c0db823e04533cdc38a9d57f89a19f2085879f02cb.png | complex | <table><tr><td>Cat no.</td><td>Category</td><td>No. of questions</td></tr><tr><td colspan="2">Questionnaire 1 (QS1)</td><td>24</td></tr><tr><td>n/a</td><td>Have you ever heard of <i>masese</i>a?</td><td>1</td></tr><tr><td>1</td><td>Acquisition & transmission of <i>T. solium</i> infections</td><td>3</td></tr><tr><td>2</td><td>Acquisition of NCC</td><td>2</td></tr><tr><td>3</td><td>TS in general</td><td>3</td></tr><tr><td>4</td><td>NCC in general</td><td>3</td></tr><tr><td>5</td><td>PCC diagnosis</td><td>4</td></tr><tr><td>6</td><td>PCC treatment</td><td>2</td></tr><tr><td>7</td><td>Relationship between PCC/TS/NCC</td><td>3</td></tr><tr><td>8</td><td>Prevention of PCC/TS/NCC</td><td>3</td></tr><tr><td colspan="2">Questionnaire 2 (QS2)</td><td>15</td></tr><tr><td>1</td><td>General knowledge</td><td>5</td></tr><tr><td>2</td><td>Transmission</td><td>5</td></tr><tr><td>3</td><td>Prevention</td><td>5</td></tr></table> |
155dcd3e15cacbd46fedd8c903d4b3291629a27923b11ce6bd80ebae47f5b6a8.png | simple | <table><tr><td><i>CD274/PD-L1</i> FISH</td><td>Cases</td><td>PD-L1 IHC</td><td></td><td></td><td></td></tr><tr><td></td><td><i>n</i> = 80</td><td>Score3+</td><td>Score2+</td><td>Score1+</td><td>Score0</td></tr><tr><td>High Level Amplification</td><td>12 (15%)</td><td>7/12</td><td>1/12</td><td>2/12</td><td>2/12</td></tr><tr><td>Low Level Amplification</td><td>3 (4%)</td><td>1/3</td><td>0/3</td><td>0/3</td><td>2/3</td></tr><tr><td>Polysomy</td><td>16 (20%)</td><td>3/16</td><td>3/16</td><td>3/16</td><td>7/16</td></tr><tr><td>Disomy</td><td>49 (61%)</td><td>3/49</td><td>8/49</td><td>5/49</td><td>33/49</td></tr></table> |
544e4eb350941ed21f388455939329039a819a7aa14bb303a488a9f84657ef03.png | simple | <table><tr><td> </td><td>Total (N=60)</td><td>Group 1 (N=39, 65%)</td><td>Group 2 (N=21, 35%)</td><td><i>P </i>value</td></tr><tr><td>HPV-HR</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Positive</td><td>23 (56)</td><td>14 (61)</td><td>9 (50)</td><td>0.54</td></tr><tr><td>Negative</td><td>18 (44)</td><td>9 (39)</td><td>9 (50)</td><td> </td></tr><tr><td>HPV-16/18</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Positive</td><td>15 (37)</td><td>8 (35)</td><td>7 (39)</td><td>1</td></tr><tr><td>Negative</td><td>26 (63)</td><td>15 (65)</td><td>11 (61)</td><td> </td></tr><tr><td>p16</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Positive</td><td>27 (66)</td><td>16 (70)</td><td>11 (61)</td><td>0.74</td></tr><tr><td>Negative</td><td>14 (34)</td><td>7 (30)</td><td>7 (39)</td><td> </td></tr><tr><td>Cyclin D1</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Positive</td><td>12 (29)</td><td>4 (17)</td><td>8 (44)</td><td> </td></tr><tr><td>Negative</td><td>29 (71)</td><td>19 (83)</td><td>10 (56)</td><td>0.09</td></tr></table> |
7b18d8b726f82e1b80ab6b07eb34f2c08fa5aa0bebc16825d349e2301c3e8e90.png | simple | <table><tr><td>Statement</td><td>Agree (%)</td><td>Disagree (%)</td><td>? (%)</td></tr><tr><td>1. A man doesn't reach a orgasm during sexual intercourse. Still, the woman can become pregnant.</td><td>50</td><td>34</td><td>16</td></tr><tr><td>2. It is unhealthy to use the oral contraceptive pill for a period longer than 10 years.</td><td>44</td><td>14</td><td>42</td></tr><tr><td>3. If a woman uses the oral contraceptive pill, she can become infertile.</td><td>22</td><td>60</td><td>18</td></tr><tr><td>4. If a woman uses the oral contraceptive pill, her desire for sex becomes less.</td><td>7</td><td>73</td><td>20</td></tr><tr><td>5. The oral contraceptive pill is the most reliable contraceptive method.</td><td>49</td><td>43</td><td>8</td></tr><tr><td>6. The injectable contraceptive contains hormones, just as the oral contraceptive pill.</td><td>63</td><td>6</td><td>31</td></tr><tr><td>7. An intrauterine device can reside in the uterus without problems for 5 years.</td><td>42</td><td>20</td><td>38</td></tr><tr><td>8. A condom is not reliable because it ruptures rapidly.</td><td>39</td><td>53</td><td>8</td></tr></table> |
25e0fe3b39008208ea823b47f8d4fd9c4cdac157a2cc54aa8aff4ae4ad46d21a.png | simple | <table><tr><td></td><td>Without vaccination</td><td>With vaccination<sup>a</sup></td><td>Difference</td></tr><tr><td>Cases<sup>b</sup></td><td>59,495</td><td>25,281</td><td>34,214</td></tr><tr><td> Treated at home</td><td>47,622</td><td>22,389</td><td>25,232</td></tr><tr><td> GP visits</td><td>11,453</td><td>2,786</td><td>8,667</td></tr><tr><td> Hospitalised (community acquired)</td><td>2,817</td><td>353</td><td>2,464</td></tr><tr><td> Hospitalised (nosocomial)</td><td>421</td><td>106</td><td>315</td></tr><tr><td> Deaths</td><td>0.65</td><td>0.16</td><td>0.48</td></tr><tr><td>Total QALYs lost<sup>c</sup></td><td>173</td><td>64</td><td>109</td></tr><tr><td>Total direct costs<sup>a </sup>(x1000)<sup>c</sup></td><td>€ 7,470</td><td>€ 1,185</td><td>€ 6,282</td></tr><tr><td>Total indirect costs (x1000) <sup>c</sup></td><td>€ 2,193</td><td>€ 888</td><td>€ 1,305</td></tr></table> |
768a87741a04e7130686072f35025fffbfc372e5127aff85c7c1fbd5b45af6c6.png | complex | <table><tr><td rowspan="2" colspan="2">Characteristics</td><td>HCC n(%)</td><td>CHB n(%)</td><td>HEAL n(%)</td><td><i>P </i>value</td></tr><tr><td>n = 392</td><td>n = 344</td><td>n = 372</td><td> </td></tr><tr><td rowspan="2">Age</td><td><55</td><td>252(64.3)</td><td>223(64.8)</td><td>245(65.9)</td><td>0.90</td></tr><tr><td>≥55</td><td>140(35.7)</td><td>121(35.2)</td><td>127(34.1)</td><td> </td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>345(88.0)</td><td>267(77.6)</td><td>306(82.3)</td><td>0.001</td></tr><tr><td>Female</td><td>47(12.0)</td><td>77(22.4)</td><td>66(17.7)</td><td> </td></tr><tr><td rowspan="2">Alcohol abuse</td><td>Absent</td><td>75(19.1)</td><td>44(12.8)</td><td>31(8.3)</td><td><0.001</td></tr><tr><td>Present</td><td>317(80.9)</td><td>300(87.2)</td><td>341(91.7)</td><td> </td></tr><tr><td rowspan="2">Cirrhosis</td><td>Absent</td><td>50(12.8)</td><td>331(96.2)</td><td>372</td><td> </td></tr><tr><td>Present</td><td>342(87.2)</td><td>13(3.8)</td><td>0</td><td> </td></tr><tr><td>Anti-HCV positive</td><td> </td><td>0</td><td>0</td><td>0</td><td> </td></tr><tr><td>HBsAg positive</td><td> </td><td>364(92.9)</td><td>344(100.0)</td><td>0</td><td> </td></tr><tr><td>AFP(ng/ml)</td><td> </td><td>923.3 ± 597.1</td><td>7.6 ± 6.9</td><td> </td><td><0.001</td></tr><tr><td>ALT(IU/L)</td><td> </td><td>51.0 ± 24.0</td><td>54.0 ± 41.0</td><td>21.0 ± 8.1</td><td>0.30</td></tr><tr><td>AST(IU/L)</td><td> </td><td>36.3 ± 29.4</td><td>45.3 ± 34.3</td><td>26.1 ± 6.9</td><td>0.67</td></tr><tr><td>GGT(IU/L)</td><td> </td><td>27.7 ± 23.5</td><td>39.4 ± 35.7</td><td>19.5 ± 17.1</td><td>0.56</td></tr><tr><td>TBIL(μmol/L)</td><td> </td><td>16.4 ± 12.6</td><td>19.0 ± 7.3</td><td>12.1 ± 4.2</td><td>0.56</td></tr></table> |
2a41e6d30882308285bfff49169a7fb131f9faf7360ead77a4f975c9dc79df67.png | complex | <table><tr><td>Data set</td><td colspan="3">Variance component (%)</td></tr><tr><td></td><td>Among groups</td><td>Among populations within group</td><td>Within populations</td></tr><tr><td>All six cattle breeds</td><td>7.80</td><td>0.70</td><td>91.45</td></tr><tr><td>Indigenous and local developed breeds</td><td>7.80</td><td>1.40</td><td>90.80</td></tr></table> |
960edf1682277fc8d8ac4accdd1ad28cebc0ad3d40a5353d8de7d4d283d80621.png | complex | <table><tr><td rowspan="2">Individual/Demographic</td><td colspan="5">Total Leisure Time Physical Activity (LTPA)</td></tr><tr><td>(ALL) <i>n</i> = 428</td><td>T1 <i>n</i> = 143</td><td>T2 <i>n</i> = 142</td><td>T3 <i>n</i> = 143</td><td><i>p</i> Trend</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td><0.001</td></tr><tr><td>Men</td><td>182 (42.5%)</td><td>49 (34.3%)</td><td>51 (35.9%)</td><td>82 (57.3%)</td><td></td></tr><tr><td>Women</td><td>246 (57.5%)</td><td>94 (65.7%)</td><td>91 (64.1%)</td><td>61 (42.7%)</td><td></td></tr><tr><td>Age (years) </td><td>68.0 (63.0;72.0)</td><td>67.0 (62.0;71.0)</td><td>68.0 (63.0;72.0)</td><td>69.0 (65.0;73.0)</td><td>0.016</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>30.0 (27.5;32.1)</td><td>30.9 (28.3;33.0)</td><td>29.7 (27.4;31.8)</td><td>29.9 (27.2;31.6)</td><td>0.012</td></tr><tr><td>Educational Level</td><td></td><td></td><td></td><td></td><td>0.159</td></tr><tr><td>Primary school or lesser</td><td>365 (85.9%)</td><td>125 (87.4%)</td><td>125 (88.7%)</td><td>115 (81.6%)</td><td></td></tr><tr><td>Secondary School or greater</td><td>60 (14.1%)</td><td>18 (12.6%)</td><td>16 (11.3%)</td><td>26 (18.4%)</td><td></td></tr><tr><td>Smoking status</td><td></td><td></td><td></td><td></td><td>0.008</td></tr><tr><td>Former</td><td>118 (27.6%)</td><td>31 (21.7%)</td><td>28 (19.7%)</td><td>59 (41.3%)</td><td></td></tr><tr><td>Current</td><td>70 (16.4%)</td><td>31 (21.7%)</td><td>25 (17.6%)</td><td>14 (9.79%)</td><td></td></tr><tr><td>Never</td><td>240 (56.1%)</td><td>81 (56.6%)</td><td>89 (62.7%)</td><td>70 (49.0%)</td><td></td></tr><tr><td>Total LTPA (METs min/day)</td><td>198 (93.8;330)</td><td>50.1 (14.6;93.7)</td><td>198 (160;226)</td><td>432 (330;573)</td><td><0.001</td></tr><tr><td>Light LTPA (METs min/day)</td><td>87.9 (14.0;176)</td><td>28.0 (0.00;70.0)</td><td>140 (76.0;173)</td><td>177 (44.4;298)</td><td><0.001</td></tr><tr><td>Moderate-vigorous LTPA (METs min/day)</td><td>49.5 (6.03;179)</td><td>8.00 (0.00;24.0)</td><td>57.6 (8.01;132)</td><td>277 (123;455)</td><td><0.001</td></tr></table> |
4e4dff3af35d4ffa04880e73a46cea1f2b642db34a8f19d2530fd430a3c58035.png | complex | <table><tr><td> </td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 3</td></tr><tr><td>Characteristics</td><td>Coeff</td><td>(95% CI)</td><td>Coeff</td><td>95% CI</td><td>Coeff</td><td>95% CI</td></tr><tr><td>Sociodemographic</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Wealth quintile</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>First Quintile (REF)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Second Quintile</td><td>0.074</td><td>0.034, 0.115</td><td>0.056</td><td>0.017, 0.096</td><td>0.063</td><td>0.020, 0.107</td></tr><tr><td>Third Quintile</td><td>0.090</td><td>0.050, 0.130</td><td>0.068</td><td>0.030, 0.107</td><td>0.063</td><td>0.021, 0.104</td></tr><tr><td>Fourth Quintile</td><td>0.109</td><td>0.068, 0.150</td><td>0.089</td><td>0.049, 0.129</td><td>0.083</td><td>0.039, 0.126</td></tr><tr><td>Fifth Quintile</td><td>0.138</td><td>0.098, 0.177</td><td>0.100</td><td>0.061, 0.139</td><td>0.092</td><td>0.050, 0.133</td></tr><tr><td>Behavioural</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Tobacco consumption</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Never smoked (REF)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Current smoker</td><td> </td><td> </td><td>−0.084</td><td>−0.113,-0.055</td><td>−0.087</td><td>−0.120, −0.054</td></tr><tr><td>Former smoker</td><td> </td><td> </td><td>0.003</td><td>−0.025, 0.030</td><td>0.021</td><td>−0.010, 0.052</td></tr><tr><td>Snuff use</td><td> </td><td> </td><td>−0.038</td><td>−0.096, 0.020</td><td>−0.036</td><td>−0.098, 0.026</td></tr><tr><td>Chewing tobacco use</td><td> </td><td> </td><td>−0.104</td><td>−0.258, 0.050</td><td>−0.05</td><td>−0.200, 0.100</td></tr><tr><td>Diet</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Vegetable servings/week</td><td> </td><td> </td><td>0.001</td><td>−0.000, 0.001</td><td> </td><td> </td></tr><tr><td>Bread slices/week</td><td> </td><td> </td><td>0.001</td><td>0.000, 0.002</td><td>0.001</td><td>0.001, 0.003</td></tr><tr><td>Sugary drinks/week</td><td> </td><td> </td><td>0.003</td><td>−0.001, 0.007</td><td> </td><td> </td></tr><tr><td>Biological</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Self-reported Diabetes</td><td> </td><td> </td><td> </td><td> </td><td>0.099</td><td>0.023, 0.175</td></tr><tr><td>Tested HIV positive</td><td> </td><td> </td><td> </td><td> </td><td>−0.066</td><td>−0.113, −0.019</td></tr><tr><td>Reported tuberculosis</td><td> </td><td> </td><td> </td><td> </td><td>−0.082</td><td>−0.118, −0.045</td></tr><tr><td>R<sup>2</sup></td><td>0.075</td><td> </td><td>0.16</td><td> </td><td>0.196</td><td> </td></tr><tr><td>∆R<sup>2</sup></td><td> </td><td> </td><td>0.074</td><td> </td><td>0.036</td><td> </td></tr><tr><td>F (p-value)</td><td><0.001</td><td> </td><td><0.001</td><td> </td><td><0.001</td><td> </td></tr><tr><td>BIC</td><td>−702.152</td><td> </td><td>−719.666</td><td> </td><td>−561.063</td><td> </td></tr></table> |
ad39153977dcf1a03e4653fb6e48913bcd02f7e814c7401bc519b7d93c07ff60.png | simple | <table><tr><td></td><td>Unadjusted model (OR; CI95%)</td><td>Model 1 (OR; CI95%)</td><td>Model 2 (OR; CI95%)</td><td>Model 3 (OR; CI95%)</td></tr><tr><td>Glomerular filtration rate (eGFR)</td><td></td><td></td><td></td><td></td></tr><tr><td>eGFR ≥ 60 mL/min/1.73 m<sup>2</sup></td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>eGFR 45–59 mL/min/1.73 m<sup>2</sup></td><td>2.07 (1.5-2.8)</td><td>1.2 (0.9-1.7)</td><td>1.2 (0.9-1.8)</td><td>1.2 (0.9-1.8)</td></tr><tr><td>eGFR 30–44 mL/min/1.73 m<sup>2</sup></td><td>4.6 (2.9-7.3)</td><td>2.5 (1.5-4.1)</td><td>2.3 (1.4-3.8)</td><td>2.3 (1.4-3.9)</td></tr><tr><td>eGFR < 30 mL/min/1.73 m<sup>2</sup></td><td>8.4 (3.6-19.9)</td><td>4.3 (1.7-10.7)</td><td>4.1 (1.6-10.2)</td><td>4.1 (1.6-10.2)</td></tr><tr><td>For each unit below 60 mL/min/1.73 m<sup>2</sup></td><td>1.072 (1.06-1.09)</td><td>1.045 (1.03-1.06)</td><td>1.042 (1.02-1.06)</td><td>1.043 (1.02-1.06)</td></tr><tr><td>UACR</td><td></td><td></td><td></td><td></td></tr><tr><td>Normoalbuminuria</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Microlbuminuria (30–299 mg/gr)</td><td>1.9 (1.4-2.7)</td><td>1.8 (1.2-2.6)</td><td>1.8 (1.3-2.7)</td><td>1.6 (1.1-2.4)</td></tr><tr><td>Macroalbuminuria (≥300 mg/gr)</td><td>5.0 (2.3-11.1)</td><td>4.6 (1.9-10.9)</td><td>4.2 (1.8-10.2)</td><td>3.9 (1.6 -9.5)</td></tr><tr><td>For each unit above 29 mg/gr</td><td>1.001 (0.99-1.01)</td><td>1.001 (0.99-1.01)</td><td>1.001 (0.99-1.01)</td><td>1.001 (0.99-1.01)</td></tr><tr><td>UACR (normal) + GFR (normal)</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>UACR ↑ and eGFR ↓</td><td>3.3 (1.5-7.3)</td><td>2.3 (1.0-5.3)</td><td>2.4 (1.0-5.4)</td><td>2.2 (0.9-5.2)</td></tr></table> |
b5fa861a6c0a333080566b6475ffe3381847b0e2c1296a314b6a65003d597fa0.png | complex | <table><tr><td> </td><td colspan="2">Bayes Factor 10</td><td colspan="2">Bayes Factor 30</td><td colspan="2">Bayes Factor 50</td></tr><tr><td> </td><td>Blood</td><td>Brush</td><td>Blood</td><td>Brush</td><td>Blood</td><td>Brush</td></tr><tr><td>Mean # CNVS per subject</td><td>314.0</td><td>385.7</td><td>151.5</td><td>183.0</td><td>103.1</td><td>109.1</td></tr><tr><td colspan="7">Size of CNVs (kb)</td></tr><tr><td>Mean</td><td>15.9</td><td>16.2</td><td>19.9</td><td>19.0</td><td>19.4</td><td>19.0</td></tr><tr><td>25th percentile</td><td>1.0</td><td>1.1</td><td>1.0</td><td>1.1</td><td>1.1</td><td>1.2</td></tr><tr><td>Median</td><td>2.1</td><td>2.1</td><td>1.9</td><td>2.1</td><td>1.9</td><td>2.0</td></tr><tr><td>75th percentile</td><td>6.0</td><td>5.8</td><td>4.4</td><td>4.8</td><td>3.9</td><td>4.2</td></tr><tr><td colspan="7">Size of CNVs (probes)</td></tr><tr><td>Mean</td><td>15.9</td><td>16.6</td><td>17.2</td><td>18.4</td><td>17.9</td><td>17.0</td></tr><tr><td>25th percentile</td><td>12.0</td><td>12.0</td><td>13.0</td><td>14.0</td><td>14.0</td><td>14.0</td></tr><tr><td>Median</td><td>16.0</td><td>16.0</td><td>17.0</td><td>17.0</td><td>17.0</td><td>17.0</td></tr><tr><td>75th percentile</td><td>18.0</td><td>18.0</td><td>18.0</td><td>18.0</td><td>18.0</td><td>18.0</td></tr></table> |
c2c50d4447415b878adf73b52e0e0e301622ea6fdb6a87f6f605e53bf556f245.png | complex | <table><tr><td></td><td colspan="4">Practices in first cohort</td><td colspan="2">Practices in second cohort</td></tr><tr><td>Practice characteristic</td><td colspan="2">2006-2008</td><td colspan="2">2009-2011</td><td colspan="2">2009-2011</td></tr><tr><td></td><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>Practice type</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Single handed</td><td>17</td><td>25%</td><td>18</td><td>26%</td><td>19</td><td>27%</td></tr><tr><td>Health center</td><td>10</td><td>14%</td><td>11</td><td>16%</td><td>8</td><td>12%</td></tr><tr><td>Other</td><td>42</td><td>61%</td><td>40</td><td>58%</td><td>42</td><td>61%</td></tr><tr><td>Practice location<sup>1</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Urban</td><td>23</td><td>33%</td><td>23</td><td>33%</td><td>25</td><td>36%</td></tr><tr><td>Semi-urban</td><td>34</td><td>49%</td><td>34</td><td>49%</td><td>33</td><td>48%</td></tr><tr><td>Rural</td><td>12</td><td>18%</td><td>12</td><td>18%</td><td>11</td><td>16%</td></tr><tr><td>Average number of patients per practice</td><td>4629</td><td></td><td>4808</td><td></td><td>4830</td><td></td></tr></table> |
741e594f762f5ab3686054f02af8a0c325f5259caf1e84675ec99ae3c5898f66.png | complex | <table><tr><td></td><td colspan="2">Females</td><td colspan="2">Males</td></tr><tr><td></td><td>Control</td><td>Prenatal stress</td><td>Control</td><td>Prenatal stress</td></tr><tr><td>P1</td><td>6.4 ± 1.1</td><td>5.9 ± 1.5<sup><i>aa</i></sup></td><td>6.7 ± 1.3</td><td>6.2 ± 1.6</td></tr><tr><td>P21</td><td>40.8 ± 2.4</td><td>39.8 ± 2.1</td><td>39.5 ± 2.2</td><td>43.2 ± 2.7</td></tr><tr><td>P28</td><td>57.8 ± 2.9</td><td>64.8 ± 2.7<sup><i>a</i></sup></td><td>68.2 ± 2.5</td><td>66.2 ± 2.8</td></tr></table> |
9aecdc9ee349f5dc3eb68074538aedee75eefb37c0eed27f3b51bcf26dbd896a.png | simple | <table><tr><td>Storage time</td><td>Test organism exposed to (name of the test)</td><td><i>Staphylococcus </i><i>aureus</i></td><td><i>Staphylococcus </i><i>epidermidis</i></td><td><i>Micrococcus </i><i>luteus</i></td><td><i>Corynebacterium </i><i>jeikeium</i></td><td><i>Candida </i><i>albicans</i></td></tr><tr><td>< 1 min</td><td>neutralizer in saline peptone water (neutralizer toxicity test)</td><td>1.86 ± 0.05</td><td>1.81 ± 0.03</td><td>1.77 ± 0.01</td><td>1.82 ± 0.02</td><td>2.05 ± 0.01</td></tr><tr><td></td><td>antiseptic solution (material control test)</td><td>0*</td><td>0*</td><td>0*</td><td>0*</td><td>0*</td></tr><tr><td></td><td>saline peptone water (organism viability test)</td><td>1.90 ± 0.05</td><td>1.84 ± 0.07</td><td>1.74 ± 0.03</td><td>1.79 ± 0.02</td><td>2.02 ± 0.03</td></tr><tr><td>3 h</td><td>neutralizer in saline peptone water (neutralizer toxicity test)</td><td>1.83 ± 0.02</td><td>1.81 ± 0.02</td><td>1.72 ± 0.03</td><td>1.89 ± 0.08</td><td>2.05 ± 0.06</td></tr><tr><td></td><td>antiseptic solution (material control test)</td><td>0*</td><td>0*</td><td>0*</td><td>0*</td><td>0*</td></tr><tr><td></td><td>saline peptone water (organism viability test)</td><td>1.88 ± 0.06</td><td>1.81 ± 0.02</td><td>1.73 ± 0.05</td><td>1.77 ± 0.08</td><td>2.03 ± 0.02</td></tr></table> |
e6e0e23b696d989b45073f908b705b77c8be2ca03b3e171fde698ff0b6550374.png | complex | <table><tr><td>Samples</td><td>Number</td><td>Gender</td><td>Age</td><td>Mean age</td></tr><tr><td rowspan="2">Controls (<i>n</i> = 15)</td><td>7</td><td>Male</td><td>32–77</td><td>51.1 ± 15.3</td></tr><tr><td>8</td><td>Female</td><td>46–61</td><td>52.6 ± 4.9</td></tr><tr><td rowspan="2">Symptomatic HD (<i>n</i> = 16)</td><td>8</td><td>Male</td><td>48–65</td><td>60.6 ± 5.6</td></tr><tr><td>8</td><td>Female</td><td>46–67</td><td>55.2 ± 7.3</td></tr></table> |
7584b08123aa0daca04d1c4dfffe29b132dea2be37122d91e502045cae43e0f6.png | simple | <table><tr><td>Haplotype</td><td>case(frequency)</td><td>control(frequency)</td><td><i>P</i>-value</td><td>OR(95% CI)</td></tr><tr><td>C G G</td><td>323.66 (0.680)</td><td>852.26 (0.670)</td><td>0.745</td><td>1.039 [0.826~ 1.306]</td></tr><tr><td>G A A</td><td>103.66 (0.218)</td><td>324.60 (0.255)</td><td>0.099</td><td>0.809 [0.629~ 1.041]</td></tr><tr><td>G GG</td><td>42.34 (0.089)</td><td>74.71 (0.059)</td><td>0.025*</td><td>1.561 [1.054~ 2.312]</td></tr><tr><td>Global result</td><td></td><td></td><td>0.034</td><td></td></tr></table> |
57bdb587c82f5865aec8c1b9f177aaa42846a5c9d14a7c2af4d9b24c2bd403ab.png | simple | <table><tr><td>Age group</td><td>Number of patients with condylar changes</td></tr><tr><td>20–40 (Group A)</td><td>16 (64%)</td></tr><tr><td>41–60 (Group B)</td><td>22 (88%)</td></tr><tr><td>61 and above (Group C)</td><td>23 (92%)</td></tr></table> |
913f014ffbea8633132e62f8cb31e809fbf402252ebcc101043ce535662d79a8.png | simple | <table><tr><td>MiRNA</td><td>Control</td><td>p16 Carriers</td><td><i>p</i> Value</td></tr><tr><td>hsa-let-7b</td><td>0.118 ± 0.001</td><td>0.104 ± 0.012</td><td>0.217</td></tr><tr><td>hsa-let-7g</td><td>0.056 ± 0.007</td><td>0.051 ± 0.011</td><td>0.350</td></tr><tr><td>hsa-miR-125b</td><td>1.319 ± 0.125</td><td>1.251 ± 0.150</td><td>0.368</td></tr><tr><td>hsa-miR-126</td><td>0.113 ± 0.019</td><td>0.127 ± 0.018</td><td>0.425</td></tr><tr><td>hsa-miR-128</td><td>2.034 ± 0.210</td><td>1.826 ± 0.206</td><td>0.242</td></tr><tr><td>hsa-miR-137</td><td>0.052 ± 0.005</td><td>0.045 ± 0.006</td><td>0.252</td></tr><tr><td>hsa-miR-148a</td><td>0.094 ± 0.011</td><td>0.083 ± 0.008</td><td>0.224</td></tr><tr><td>hsa-miR-149</td><td>0.024 ± 0.004</td><td>0.028 ± 0.006</td><td>0.310</td></tr><tr><td>hsa-miR-17</td><td>0.101 ± 0.17</td><td>0.097 ± 0.013</td><td>0.418</td></tr><tr><td>hsa-miR-199a</td><td>0.017 ± 0.004</td><td>0.016 ± 0.010</td><td>0.451</td></tr><tr><td>hsa-miR-19a</td><td>0.421 ± 0.067</td><td>0.409 ± 0.053</td><td>0.446</td></tr><tr><td>hsa-miR-19b</td><td>0.558 ± 0.090</td><td>0.543 ± 0.077</td><td>0.450</td></tr><tr><td>hsa-miR-20b</td><td>0.123 ± 0.020</td><td>0.107 ± 0.012</td><td>0.273</td></tr><tr><td>hsa-miR-21</td><td>0.775 ± 0.074</td><td>0.789 ± 0.054</td><td>0.441</td></tr><tr><td>hsa-miR-221</td><td>0.335 ± 0.030</td><td>0.311 ± 0.023</td><td>0.273</td></tr><tr><td>hsa-miR-222</td><td>0.589 ± 0.062</td><td>0.519 ± 0.062</td><td>0.182</td></tr><tr><td>hsa-miR-23a</td><td>0.520 ± 0.095</td><td>0.473 ± 0.072</td><td>0.350</td></tr><tr><td>hsa-miR-29a</td><td>0.625 ± 0.054</td><td>0.593 ± 0.044</td><td>0.323</td></tr><tr><td>hsa-miR-423-3p</td><td>0.088 ± 0.014</td><td>0.078 ± 0.006</td><td>0.264</td></tr><tr><td>hsa-miR-92a</td><td>0.341 ± 0.053</td><td>0.306 ± 0.034</td><td>0.292</td></tr></table> |
c45537c2c3bedf9f11d2887d9044aa5faa69c5acab8be8eaa708b5dab04afa8f.png | complex | <table><tr><td rowspan="2">Type of Intervention</td><td colspan="5">Overall mean blood : sweat ratio</td></tr><tr><td>BDE 28</td><td>BDE 47</td><td>BDE 99</td><td>BDE 100</td><td>BDE 153</td></tr><tr><td>Exercise (<i>n</i> = 3)</td><td>137.2</td><td>25.5</td><td>4.8</td><td>16.9</td><td>26.9</td></tr><tr><td>Infrared sauna (<i>n</i> = 8)</td><td>17.9</td><td>32.1</td><td>3.25</td><td>94.6</td><td>71.8</td></tr><tr><td>Steam sauna (<i>n</i> = 6)</td><td>69.5</td><td>26.3</td><td>5.6</td><td>2.4</td><td>121.2</td></tr></table> |
d77a85ad52899e59c0617fa6caf3ca52a34b520b5c9e2490e9c5c8a94e112c96.png | complex | <table><tr><td>Key barriers</td><td>Key facilitators</td></tr><tr><td>Capabilities: Stress associated with being an asylum seeker</td><td>Stress drove activity</td></tr><tr><td>Decision process: Living in limbo</td><td>Feeling settled and secure</td></tr><tr><td>Resources and environment Lack of money for food and equipment Lack of knowledge of facilities in local area The weather Time Lack of childcare</td><td></td></tr><tr><td colspan="2">Social</td></tr><tr><td> Exercising With friends/ family Alone in the UK Cultural influences</td><td>Exercising With friends/ family</td></tr><tr><td colspan="2">Knowledge and skills</td></tr><tr><td> The phrase ‘physical activity’ and recommended levels</td><td>Levels of exercise and physical activity back home</td></tr><tr><td></td><td>Understanding consequences Impact on physical health Weight gain Impact on mental health</td></tr></table> |
5b7631cf3e2000fff71b92af7118bc04eb1cb4e711e6543390d98fd71b75aa89.png | simple | <table><tr><td>Disease</td><td>miRNA</td><td>Expression level</td><td>Contributors</td></tr><tr><td>Breast cancer</td><td>miR-29a</td><td>Up-regulation</td><td>Wu et al., J Biomed Biotechnol. (2010) [76]</td></tr><tr><td> </td><td>miR-21</td><td> </td><td>Asaga et al., Clin Chem. (2011) [77]</td></tr><tr><td>Lung cancer</td><td>miR-21,1254,574-5p</td><td>Up-regulation</td><td>Wei et al., Chin J Cancer. (2011) [79]</td></tr><tr><td> </td><td> </td><td> </td><td>Foss et al., J Thorac Oncol. (2011) [78]</td></tr><tr><td>Hepatocellular carcinoma</td><td>miR-16,miR-199a</td><td>Down-regulation</td><td>Qu et al., J Clin Gastroenterol. (2011) [80]</td></tr><tr><td> </td><td>miR-21,miR-122,miR-223</td><td>Up-regulation</td><td>Xu et al., Mol Carcinog. (2010) [81]</td></tr><tr><td>Malignant melanoma</td><td>miR-221</td><td>Up-regulation</td><td>Kanemaru et al., J Dermatol Sci. (2011) [82]</td></tr><tr><td>Gastric cancer</td><td>miR-1,20a,27a,34,423-5p</td><td>Up-regulation</td><td>Liu et al., Eur J Cancer. (2011) [83]</td></tr></table> |
584d3b6079e9b6e4799d9ec23a843aaeade7d4864fb1d17ef5f83699b2c0f3ff.png | simple | <table><tr><td>Categories</td><td>Cohorts (<i>n</i>)</td><td>HR (95%CI)</td><td><i>P</i> value</td><td><i>I</i><sup>2</sup> (%)</td><td>Model types</td></tr><tr><td>OS</td><td>8 (4448)</td><td>0.99 (0.77–1.27)</td><td>0.96</td><td>82</td><td>Random-effects</td></tr><tr><td>PFS</td><td>3 (2861)</td><td>1.26 (1.15–1.39)</td><td><0.00001</td><td>32</td><td>Fixed-effects</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td><td>Random-effects</td></tr><tr><td>Asian</td><td>4 (1879)</td><td>0.97 (0.72–1.32)</td><td>0.85</td><td>76</td><td></td></tr><tr><td>Caucasian</td><td>4 (2569)</td><td>1.03 (0.65–1.63)</td><td>0.90</td><td>86</td><td></td></tr><tr><td>Median follow-up time (months)</td><td></td><td></td><td></td><td></td><td>Random-effects</td></tr><tr><td>>60</td><td>4 (2540)</td><td>1.12 (0.89–1.42)</td><td>0.11</td><td>51</td><td></td></tr><tr><td><60</td><td>4 (1908)</td><td>0.98 (0.64–1.48)</td><td>0.91</td><td>87</td><td></td></tr><tr><td>Mean age (years)</td><td></td><td></td><td></td><td></td><td>Random-effects</td></tr><tr><td>>50</td><td>5 (2497)</td><td>0.92 (0.62–1.37)</td><td>0.69</td><td>84</td><td></td></tr><tr><td><50</td><td>3 (1951)</td><td>1.18 (0.96–1.44)</td><td>0.11</td><td>47</td><td></td></tr><tr><td>Publication year</td><td></td><td></td><td></td><td></td><td>Fixed-effects</td></tr><tr><td>Before 2010</td><td>4 (2780)</td><td>0.70 (0.60–0.83)</td><td><0.0001</td><td>0</td><td></td></tr><tr><td>After 2010</td><td>4 (1668)</td><td>1.26 (1.13–1.41)</td><td><0.00001</td><td>0</td><td></td></tr><tr><td>Specimen sources</td><td></td><td></td><td></td><td></td><td>Fixed-effects</td></tr><tr><td>Serum</td><td>5 (2875)</td><td>1.24 (1.11–1.38)</td><td><0.0001</td><td>42</td><td></td></tr><tr><td>Tissue</td><td>3 (1573)</td><td>0.71 (0.60–0.84)</td><td><0.00001</td><td>0</td><td></td></tr><tr><td>Testing methods</td><td></td><td></td><td></td><td></td><td>Fixed-effects</td></tr><tr><td>ELISA</td><td>4 (2575)</td><td>1.21 (1.08–1.35)</td><td>0.0001</td><td>21</td><td></td></tr><tr><td>IHC</td><td>4 (1873)</td><td>0.83 (0.71–0.96)</td><td><0.0001</td><td>84</td><td></td></tr><tr><td>Chemotherapy</td><td></td><td></td><td></td><td></td><td>Random-effects</td></tr><tr><td>With</td><td>4 (1172)</td><td>0.93 (0.65–1.33)</td><td>0.70</td><td>75</td><td></td></tr><tr><td>Without</td><td>4 (3276)</td><td>1.05 (0.69–1.59)</td><td>0.84</td><td>88</td><td></td></tr><tr><td>Segment type</td><td></td><td></td><td></td><td></td><td>Random-effects</td></tr><tr><td>M30</td><td>5 (2902)</td><td>1.17 (0.95–1.45)</td><td>0.13</td><td>69</td><td></td></tr><tr><td>M65</td><td>3 (1546)</td><td>0.72 (0.61–0.86)</td><td>0.0003</td><td>0</td><td></td></tr></table> |
029f112876b2d917ab2dc89519be5bd9db4aa6829679bd428e34b713e8dd2835.png | complex | <table><tr><td></td><td>Total (<i>n</i>)</td><td>Always % (standard error)</td><td>Not in international competition</td><td>Not >10 fights</td><td>Other</td><td>Never</td></tr><tr><td>Total</td><td>431</td><td>71.5 (5.6)</td><td>7.2 (3.2)</td><td>10.7 (3.8)</td><td>4.9 (2.7)</td><td>5.8 (3.0)</td></tr><tr><td colspan="7">Sex</td></tr><tr><td> Male</td><td>310</td><td>64.2 (6.9)</td><td>8.7 (4.2)</td><td>13.9 (5.1)</td><td>5.8 (3.5)</td><td>7.4 (3.9)</td></tr><tr><td> Female**</td><td>116</td><td>90.5 (7.2)</td><td>2.6 (4.5)</td><td>2.6 (4.5)</td><td>2.6 (4.5)</td><td>1.7 (4.0)</td></tr><tr><td> Unlisted</td><td>5</td><td>80 (34.7)</td><td>20 (34.7)</td><td>0 (28.5)</td><td>0 (28.5)</td><td>0 (28.5)</td></tr><tr><td colspan="7">Age</td></tr><tr><td> ≤18</td><td>32</td><td>53.1 (20.7)</td><td>15.6 (16.2)</td><td>12.5 (15.1)</td><td>9.4 (13.9)</td><td>9.4 (13.9)</td></tr><tr><td> 19–40</td><td>236</td><td>68.6 (7.7)</td><td>5.5 (4)</td><td>14 (5.8)</td><td>5.1 (3.8)</td><td>6.8 (4.3)</td></tr><tr><td> >40</td><td>160</td><td>78.8 (8.2)</td><td>8.1 (5.7)</td><td>5.6 (4.9)</td><td>3.8 (4.2)</td><td>3.8 (4.2)</td></tr><tr><td> Unlisted</td><td>3</td><td>100 (34.4)</td><td>0 (34.4)</td><td>0 (34.4)</td><td>0 (34.4)</td><td>0 (34.4)</td></tr><tr><td colspan="7">Role</td></tr><tr><td> Active boxer*</td><td>154</td><td>58.4 (10.0)</td><td>9.7 (6.3)</td><td>18.8 (8)</td><td>7.1 (5.5)</td><td>5.8 (5.1)</td></tr><tr><td> Retired boxer</td><td>113</td><td>77.9 (9.9)</td><td>6.2 (6.2)</td><td>7.1 (6.5)</td><td>4.4 (5.5)</td><td>4.4 (5.5)</td></tr><tr><td> Parent of boxer</td><td>53</td><td>86.8 (12.0)</td><td>5.7 (9.2)</td><td>3.8 (8.2)</td><td>1.9 (7.0)</td><td>1.9 (7.0)</td></tr><tr><td> Coach</td><td>169</td><td>74.6 (8.5)</td><td>5.9 (4.9)</td><td>7.7 (5.4)</td><td>5.3 (4.7)</td><td>6.5 (5.1)</td></tr><tr><td> Official</td><td>44</td><td>77.3 (15.6)</td><td>4.5 (9.6)</td><td>9.1 (11.7)</td><td>0 (6.6)</td><td>9.1 (11.7)</td></tr><tr><td> Administrator</td><td>41</td><td>82.9 (14.8)</td><td>7.3 (11.4)</td><td>4.9 (10.2)</td><td>4.9 (10.2)</td><td>0 (7.0)</td></tr><tr><td> Fan</td><td>20</td><td>75 (22.5)</td><td>5 (15.6)</td><td>10 (18.0)</td><td>5 (15.6)</td><td>5 (15.6)</td></tr><tr><td> Other</td><td>9</td><td>88.9 (26.3)</td><td>0 (21.2)</td><td>11.1 (26.3)</td><td>0 (21.2)</td><td>0 (21.2)</td></tr></table> |
5e8f26ca629c797d09c5c289251edb3406337fdfb3c034f50eef8fdf5b218d6d.png | complex | <table><tr><td></td><td></td><td colspan="2">Southern zone</td><td colspan="2">Middle zone</td><td colspan="2">Northern zone</td></tr><tr><td>Indication</td><td>Medicine name</td><td>Before</td><td>After</td><td>Before</td><td>After</td><td>Before</td><td>After</td></tr><tr><td>Malaria</td><td>ACTs</td><td>53.80</td><td>7.70</td><td>33.30</td><td>0</td><td>40.00</td><td>0</td></tr><tr><td>Asthma</td><td>Salbutamol</td><td>25.00</td><td>7.70</td><td>26.70</td><td>6.20</td><td>0</td><td>20.00</td></tr><tr><td>Diabetes</td><td>Gilbendamide</td><td>38.50</td><td>30.80</td><td>20.00</td><td>18.80</td><td>60.00</td><td>60.00</td></tr><tr><td>Cardiovascular disease</td><td>Atenolol</td><td>58.30</td><td>23.10</td><td>20.00</td><td>25.00</td><td>40.00</td><td>40.00</td></tr><tr><td>Depression</td><td>Amitriptyline</td><td>58.30</td><td>38.50</td><td>33.30</td><td>50.00</td><td>60.00</td><td>60.00</td></tr><tr><td>Infectious disease</td><td>Ciprofloxacin</td><td>8.30</td><td>0</td><td>13.30</td><td>6.20</td><td>20.00</td><td>0</td></tr><tr><td>Infectious disease</td><td>Co-trimoxazole</td><td>25.00</td><td>7.70</td><td>6.00</td><td>6.20</td><td>0</td><td>0</td></tr><tr><td>Infectious disease</td><td>Amoxiillin</td><td>15.40</td><td>7.70</td><td>13.30</td><td>6.20</td><td>20.00</td><td>0</td></tr><tr><td>Central nervous system disease</td><td>Diazepam</td><td>15.40</td><td>7.70</td><td>13.30</td><td>6.20</td><td>20.00</td><td>50.00</td></tr><tr><td>Ulcer</td><td>Omeprazole</td><td>30.80</td><td>15.40</td><td>26.50</td><td>18.80</td><td>25.00</td><td>50.00</td></tr></table> |
846cb1f5d3003853b518387e131b66f531c9cb51686ffafab5ba887b76636885.png | simple | <table><tr><td>Paper</td><td># of patients</td><td>Types of mutations</td></tr><tr><td>Bartsch et al 1997 [7]</td><td>1</td><td>Translocation</td></tr><tr><td>Matsumoto et al 1997 [6]</td><td>1</td><td>Deletion</td></tr><tr><td>Møller et al 2008 [8]</td><td>2</td><td>2 translocations</td></tr><tr><td>Fujita et al 2010 [9]</td><td>1</td><td>Deletion</td></tr><tr><td>Oegema et al 2010 [10]</td><td>2</td><td>2 deletions</td></tr><tr><td>Yamamoto et al 2011 [11]</td><td>3</td><td>3 deletions</td></tr><tr><td>van Bon et al 2011 [12]</td><td>1</td><td>Deletion</td></tr><tr><td>Valetto et al 2012 [13]</td><td>1</td><td>Deletion</td></tr><tr><td>Courcet et al 2012 [14]</td><td>2</td><td>1 deletion, 1 frameshift</td></tr><tr><td>O’Roak et al 2012 [15]</td><td>3</td><td>2 frameshifts, 1 splice site</td></tr><tr><td>Okamoto et al 2015 [27]</td><td>1</td><td>Nonsense</td></tr><tr><td>Redin et al 2014 [16]</td><td>2</td><td>1 nonsense, 1 frameshift</td></tr><tr><td>Iglesias et al 2014 [17]</td><td>1</td><td>Nonsense</td></tr><tr><td>Ruaud et al 2015 [19]</td><td>2</td><td>1 nonsense, 1 missense</td></tr><tr><td>van Bon et al 2015 [18]</td><td>5</td><td>2 nonsense, 3 splice site</td></tr><tr><td>Bronicki et al 2015 [20]</td><td>10</td><td>3 nonsense, 2 missense, 4 frameshift, 1 deletion</td></tr><tr><td>Ji et al 2015 [21]</td><td>14</td><td>3 nonsense, 3 missense, 3 frameshift, 5 deletions</td></tr></table> |
8f2e462d4b51e805d6c29e56cd6367b837b47a3d375c6874c75d5886a52ead21.png | simple | <table><tr><td>Name</td><td>Origin</td><td>Sex</td><td>C14 Date (calibrated)</td><td>Endogenous (%)</td><td>Unique (%)</td><td>MT and Y haplogroup</td><td>Mean autosomal coverage</td></tr><tr><td>L</td><td>Linton</td><td>Female</td><td>360–50 BCE</td><td>72</td><td>54</td><td>H1e</td><td>1.4</td></tr><tr><td>HI1</td><td>Hinxton</td><td>Male</td><td>160 BCE–26 CE</td><td>16</td><td>63</td><td>K1a1b1b, R1b1a2a1a2c</td><td>1.3</td></tr><tr><td>HI2</td><td>Hinxton</td><td>Male</td><td>170 BCE–80 CE</td><td>83</td><td>65</td><td>H1ag1, R1b1a2a1a2c1</td><td>11.8</td></tr><tr><td>O1</td><td>Oakington</td><td>Female</td><td>420–570 CE</td><td>81</td><td>50</td><td>U5a2a1</td><td>3.8</td></tr><tr><td>O2</td><td>Oakington</td><td>Female</td><td>385–535 CE</td><td>92</td><td>68</td><td>H1g1</td><td>2.7</td></tr><tr><td>O3</td><td>Oakington</td><td>Female</td><td>395–540 CE</td><td>95</td><td>64</td><td>T2a1a</td><td>8.2</td></tr><tr><td>O4</td><td>Oakington</td><td>Female</td><td>400–545 CE</td><td>67</td><td>77</td><td>H1at1</td><td>6.3</td></tr><tr><td>HS1</td><td>Hinxton</td><td>Female</td><td>666–770 CE</td><td>36</td><td>91</td><td>H2a2b1</td><td>4.4</td></tr><tr><td>HS2</td><td>Hinxton</td><td>Female</td><td>631–776 CE</td><td>42</td><td>74</td><td>K1a4a1a2b</td><td>3.8</td></tr><tr><td>HS3</td><td>Hinxton</td><td>Female</td><td>690–881 CE</td><td>16</td><td>71</td><td>H2a2a1</td><td>0.9</td></tr></table> |
969a66b2f39e00eeae5ed0acd6b78bd20291b10cd78a407c1c973cb5bd1efdfc.png | simple | <table><tr><td>Evaluation criteria</td><td>Medium range contacts</td><td>Long range contacts</td></tr><tr><td>Top L/5</td><td>.34 (.18)</td><td>.30 (.05)</td></tr><tr><td>Top L/5, δ = 1</td><td>.55 (.27)</td><td>.48 (.07)</td></tr><tr><td>Top L/5, δ = 2</td><td>.64 (.29)</td><td>.56 (.08)</td></tr></table> |
348908255ef231154a776d363b43fa8ac46a8164020cb21af9c707a642151cc2.png | complex | <table><tr><td rowspan="2">MRSA outbreaks</td><td colspan="4">Number of days</td><td></td><td colspan="8">Validity</td></tr><tr><td>TP</td><td>FP</td><td>FN</td><td>TN</td><td></td><td>Se</td><td>(95% CI)</td><td>Sp</td><td>(95% CI)</td><td>PPV</td><td>(95% CI)</td><td>NPV</td><td>(95% CI)</td></tr><tr><td>All</td><td>10</td><td>27</td><td>39</td><td>722</td><td></td><td>20</td><td>(10–34)</td><td>96</td><td>(95–98)</td><td>27</td><td>(16–42)</td><td>95</td><td>(92–96)</td></tr><tr><td>Any hospital</td><td>5</td><td>13</td><td>25</td><td>755</td><td></td><td>17</td><td>(6–35)</td><td>98</td><td>(97–99)</td><td>28</td><td>(13–50)</td><td>97</td><td>(96–97)</td></tr><tr><td>University hospital</td><td>0</td><td>1</td><td>8</td><td>791</td><td></td><td>0</td><td></td><td>100</td><td>(99–100)</td><td>0</td><td></td><td>99</td><td>(99–99)</td></tr><tr><td>General hospital</td><td>5</td><td>12</td><td>17</td><td>764</td><td></td><td>23</td><td>(8–45)</td><td>98</td><td>(97–99)</td><td>29</td><td>(14–52)</td><td>98</td><td>(97–98)</td></tr><tr><td>Any hospital and unknown location</td><td>6</td><td>12</td><td>33</td><td>747</td><td></td><td>15</td><td>(6–31)</td><td>98</td><td>(97–99)</td><td>33</td><td>(17–56)</td><td>96</td><td>(95–96)</td></tr><tr><td>University hospital and unknown location</td><td>0</td><td>1</td><td>17</td><td>783</td><td></td><td>0</td><td></td><td>100</td><td>(99–100)</td><td>0</td><td></td><td>98</td><td>(98–98)</td></tr><tr><td>General hospital and unknown location</td><td>6</td><td>11</td><td>25</td><td>756</td><td></td><td>19</td><td>(7–37)</td><td>99</td><td>(97–99)</td><td>35</td><td>(18–58)</td><td>97</td><td>(96–97)</td></tr><tr><td>Nursing home</td><td>1</td><td>15</td><td>6</td><td>778</td><td></td><td>13</td><td>(0–53)</td><td>98</td><td>(97–99)</td><td>6</td><td>(1–31)</td><td>99</td><td>(99–99)</td></tr><tr><td>Nursing home and unknown location</td><td>2</td><td>14</td><td>14</td><td>770</td><td></td><td>13</td><td>(2–38)</td><td>98</td><td>(97–99)</td><td>13</td><td>(3–37)</td><td>98</td><td>(98–99)</td></tr><tr><td>Other location</td><td>0</td><td>3</td><td>3</td><td>795</td><td></td><td>0</td><td></td><td>100</td><td>(99–100)</td><td>0</td><td></td><td>100</td><td>(100–100)</td></tr><tr><td>Other location and unknown location</td><td>0</td><td>3</td><td>12</td><td>786</td><td></td><td>0</td><td></td><td>100</td><td>(99–100)</td><td>0</td><td></td><td>99</td><td>(98–99)</td></tr></table> |
e4d626150dea5c0b5929f62a8bcae05b4dce6b905ec2075a82e236378563f4f0.png | complex | <table><tr><td> </td><td> </td><td>Mean fold change</td><td>Upper limit C.I</td><td>Lower limit C.I</td></tr><tr><td rowspan="2">AHPC</td><td>Overexpressed in virulent strains compared to the avirulent ATCC 33658 T</td><td> </td><td> </td><td> </td></tr><tr><td>Transcription Ratio of AHPC in the virulent strains compared to ATCC 33658 T:</td><td>5.80E + 01</td><td>1.38E + 02</td><td>2.17E + 01</td></tr><tr><td>ATP-F</td><td>Overexpressed under iron-deprived conditions</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:</td><td>2.50E + 01</td><td>4.73E + 01</td><td>1.32E + 01</td></tr><tr><td>Enolase</td><td>Overexpressed under iron-deprived conditions</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:</td><td>6.10E + 02</td><td>2.23E + 03</td><td>1.68E + 02</td></tr><tr><td>H-NS</td><td>Under-expressed under iron-deprived conditions</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Transcription Ratio of the iron-rich cultures compared to the iron-poor ones:</td><td>1.89E + 03</td><td>3.29E + 03</td><td>1.09E + 03</td></tr><tr><td>VapA</td><td>Overexpressed under iron-deprived conditions</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:</td><td>3.65E + 01</td><td>5.14E + 01</td><td>2.64E + 01</td></tr></table> |
a392fb70296f762dc67e14d63abdb4f27eb6cb69c8c5a47de459d457907a28ee.png | complex | <table><tr><td>Years of formal education</td><td>Frequency (% out of n=43)</td><td>Frequency of Cognitive Dysfunction (%)</td><td>Frequency of normal Cognition (%)</td><td>Chi-square (x<sup>2</sup>) test</td><td>p-value</td></tr><tr><td>More than 12 years</td><td>16 (37.2)</td><td>8 (50.0)</td><td>8 (50.0)</td><td rowspan="2">2.563</td><td rowspan="2">0.11 (>0.05)</td></tr><tr><td>Less than 12 years</td><td>27 (62.8)</td><td>20 (74.1)</td><td>7 (25.9)</td></tr></table> |
41925d42ee62f9dfba3d8b421e5707d6afd19c0156b4315626e6a9cdb74620ab.png | simple | <table><tr><td>Type/site of TB</td><td>HIV-TB group</td></tr><tr><td>PTB [<i>n</i>(%)]</td><td>25 (20)*</td></tr><tr><td>EPTB [<i>n</i>(%)]</td><td>98 (80)</td></tr><tr><td>DTB [<i>n</i>(%)]</td><td>39 (32)</td></tr><tr><td>Lung + Pleura + mediastinal LN [<i>n</i>(%)]</td><td>11 (9)*</td></tr><tr><td>Pleura + RP/mesenteric LN [<i>n</i>(%)]</td><td>6 (5)</td></tr><tr><td>Lung + pleura [<i>n</i>(%)]</td><td>4 (3)</td></tr><tr><td>Ascites + RP/mesenteric LN + mediastinal LN [<i>n</i>(%)]</td><td>4 (3)</td></tr><tr><td>Ascites + hepatosplenomegaly + RP/mesenteric LN + mediastinal LN [<i>n</i>(%)]</td><td>3 (2)</td></tr><tr><td>Lung + pleura + Ascites + RP/mesenteric LN [<i>n</i>(%)]</td><td>3 (2)</td></tr><tr><td>Ascites + hepatosplenomegaly + mediastinal LN [<i>n</i>(%)]</td><td>2 (2)</td></tr><tr><td>Lung + pleura + Ascites + hepatosplenomegaly + RP/mesenteric LN [<i>n</i>(%)]</td><td>2 (2)</td></tr><tr><td>Lung + pleura + Ileocaecal + RP/mesenteric LN [<i>n</i>(%)]</td><td>2 (2)</td></tr><tr><td>Cervical LN + mediastinal LN + RP/mesenteric LN [<i>n</i>(%)]</td><td>2 (2)</td></tr><tr><td>Abdomen [<i>n</i>(%)]</td><td>23 (19)</td></tr><tr><td>Ascites + RP/mesenteric LN [<i>n</i>(%)]</td><td>8 (7)</td></tr><tr><td>Ascites + hepatosplenomegaly + RP/mesenteric LN [<i>n</i>(%)]</td><td>7 (6)</td></tr><tr><td>Ascites + hepatosplenomegaly [<i>n</i>(%)]</td><td>4 (3)</td></tr><tr><td>Ileocaecal + RP/mesenteric LN [<i>n</i>(%)]</td><td>4 (3)</td></tr><tr><td>Lymph node [<i>n</i>(%)]</td><td>16 (13)</td></tr><tr><td>Cervical [<i>n</i>(%)]</td><td>10 (8)<sup>†</sup></td></tr><tr><td>Abdominal [<i>n</i>(%)]</td><td>4 (3)</td></tr><tr><td>RP + mesenteric LN</td><td>2 (2)</td></tr><tr><td>RP LN</td><td>1 (1)</td></tr><tr><td>Periportal + mesenteric LN</td><td>1 (1)</td></tr><tr><td>Mediastinal [<i>n</i>(%)]</td><td>2 (2)</td></tr><tr><td>Pleural effusion [<i>n</i>(%)]</td><td>11 (9)</td></tr><tr><td>CNS [<i>n</i>(%)]</td><td>6 (5)</td></tr><tr><td>Meningitis [<i>n</i>(%)]</td><td>3 (2)</td></tr><tr><td>Tuberculoma [<i>n</i>(%)]</td><td>2 (2)</td></tr><tr><td>Meningitis + Tuberculoma [<i>n</i>(%)]</td><td>1 (1)</td></tr><tr><td>MTB [<i>n</i>(%)]</td><td>2 (2)</td></tr><tr><td>Pott's spine [<i>n</i>(%)]</td><td>1 (1)</td></tr></table> |
5e3aea724c51e91ad09f206c88f25096d659965e247063ca61b42cce466caeba.png | complex | <table><tr><td><i>Dataset type</i></td><td colspan="3"><i>Control dataset</i></td><td colspan="3"><i>Real sample dataset</i></td></tr><tr><td>Dataset Name</td><td>D1</td><td>D2</td><td>D3</td><td>D4</td><td>D5</td><td>D6</td></tr><tr><td>Instrument</td><td>LCQ</td><td>LTQ</td><td>LTQ/FT</td><td>LCQ</td><td>LTQ</td><td>LTQ/FT</td></tr><tr><td>Reference or notes</td><td>[46]</td><td>[55]</td><td>unpublished</td><td>[44]</td><td>[56]</td><td>unpublished</td></tr><tr><td>Sample</td><td>12 purified proteins + 23 peptides</td><td>49 purified human proteins</td><td>8 purified proteins</td><td>Human K562 cell line</td><td>Human liver</td><td>Human Liver</td></tr><tr><td>Data source</td><td>the BIATECH Institute (Bothell, WA 98011, USA)</td><td>Proteomics Standards Research Group (sPRG) [55]</td><td>Beijing proteome Research Center (Beijing 102206, China)</td><td>Open Proteomics Database (OPD)[57]</td><td>Beijing proteome Research Center (Beijing 102206, China)</td><td>Beijing proteome Research Center (Beijing 102206, China)</td></tr></table> |
e067e4beca43e1975b16e7210897953a35cd8d6a7d552adb4426bbd2f206eea0.png | simple | <table><tr><td>Group</td><td>N (Male/Female)</td><td>Maternal Age (Years)</td><td>Maternal BMI before Pregnancy</td><td>Gestational Age (Weeks)</td><td>Birth Weight (g)</td><td>Body Length (cm)</td><td>Ponderal Index (kg/m<sup>3</sup>)</td><td>Head Circumference (cm)</td><td>Placenta Weight (g)</td></tr><tr><td>NBW</td><td>12 (6/6)</td><td>31 ± 3</td><td>21.3 ± 2.2</td><td>39.1 ± 0.8</td><td>3452 ± 96</td><td>50.8 ± 1.1</td><td>26.2 ± 1.4</td><td>34.6 ± 0.8</td><td>701.2 ± 106.7</td></tr><tr><td>LBW</td><td>12 (6/6)</td><td>31 ± 4</td><td>21.1 ± 2.9</td><td>38.9 ± 0.9</td><td>2623 ± 207</td><td>49.2 ± 4.6</td><td>23.2 ± 5.2</td><td>31.9 ± 1.6</td><td>492.8 ± 38.5</td></tr><tr><td><i>p</i> value</td><td>-</td><td>0.76</td><td>0.82</td><td>0.58</td><td><0.01 **</td><td>0.34</td><td>0.02 *</td><td>0.013 *</td><td><0.01 **</td></tr></table> |
168db7e8376fedfcb07cde5a7b9c99ecceca99ff8478eb3edefacd0eb578d5b8.png | complex | <table><tr><td>Result/PCR target positivity</td><td>Interpretation/meaning</td><td>Action</td></tr><tr><td>G3PD 567 bp (+)</td><td rowspan="3">Valid results for parasite diagnosis</td><td rowspan="3">Conclude diagnostic test observation</td></tr><tr><td>pUC 316 bp (+)</td></tr><tr><td><i>L. braziliensis </i>138 bp (+)</td></tr><tr><td>G3PD 567 bp (+)</td><td rowspan="3">Valid results for parasite diagnosis despite small loss of DNA in extraction</td><td rowspan="3">Conclude diagnostic test observation</td></tr><tr><td>pUC 316 bp (-)</td></tr><tr><td><i>L. braziliensis </i>138 bp (+)</td></tr><tr><td>G3PD 567 bp (-)</td><td rowspan="3">Valid results for parasite diagnosis despite small degradation of sample</td><td rowspan="3">Conclude diagnostic test observation</td></tr><tr><td>pUC 316 bp (+)</td></tr><tr><td><i>L. braziliensis </i>138 bp (+)</td></tr><tr><td>G3PD 567 bp (-)</td><td rowspan="3">Degradation of DNA sample/presence of PCR inhibitors and/or whole DNA loss during extraction</td><td rowspan="3">Repeat diagnostic procedure since the blood sample collection</td></tr><tr><td>pUC 316 bp (-)</td></tr><tr><td><i>L. braziliensis </i>138 bp (-)</td></tr><tr><td>G3PD 567 bp (-)</td><td rowspan="3">Degradation of DNA sample before extraction</td><td rowspan="3">Repeat diagnostic procedure since the blood sample collection</td></tr><tr><td>pUC 316 bp (+)</td></tr><tr><td><i>L. braziliensis </i>138 bp (-)</td></tr><tr><td>G3PD 567 bp (+)</td><td rowspan="3">Significant DNA loss (affecting mainly parasite genome) during extraction process</td><td rowspan="3">Repeat the DNA extraction procedure</td></tr><tr><td>pUC 316 bp (-)</td></tr><tr><td><i>L. braziliensis </i>138 bp (-)</td></tr><tr><td>G3PD 567 bp (+)</td><td rowspan="3">True negative result for <i>Leishmania</i> detection assured by the positivity of quality controls</td><td rowspan="3">Conclude diagnostic test observation</td></tr><tr><td>pUC 316 bp (+)</td></tr><tr><td><i>L. braziliensis </i>138 bp (-)</td></tr></table> |
e0d684fa992ff298402b09b723e24dbabf864779eefa164ea0a444d0df324e09.png | complex | <table><tr><td colspan="2">Microtiter plate [28]</td><td colspan="2">Microtiter plate [29]</td><td colspan="2">RISE [30]</td></tr><tr><td colspan="2">Round 1 (h)</td><td colspan="2">Round 1 (h)</td><td colspan="2">Round 1 (h)</td></tr><tr><td>Target incubation</td><td>18</td><td>Target incubation</td><td>2</td><td>Target incubation</td><td>18</td></tr><tr><td>Wash-postcoat</td><td>2.25</td><td>Wash-postcoat</td><td>1.5</td><td>Wash-postcoat</td><td>4</td></tr><tr><td>Phage incubation</td><td>1</td><td>Phage incubation</td><td>1</td><td>Cell growth tubes</td><td>3</td></tr><tr><td>Wash-elution</td><td>0.5</td><td>Wash-elution</td><td>2.25</td><td>Infection</td><td>3</td></tr><tr><td>Infection</td><td></td><td>Infection</td><td></td><td>Wash</td><td>0.5</td></tr><tr><td>- amplification</td><td>4.5</td><td>- amplification</td><td>5</td><td>Cell/phage/target incubation</td><td>16</td></tr><tr><td>Phage recovery</td><td>0.5</td><td>Phage recovery</td><td>18</td><td>Phage recovery</td><td>0.5</td></tr><tr><td>Time</td><td>~27 h</td><td></td><td>~30 h</td><td></td><td>~45 h</td></tr><tr><td>2 additional panning rounds</td><td></td><td>2 additional panning rounds</td><td></td><td>3 additional panning rounds</td><td></td></tr><tr><td>TOTAL TIME</td><td>~81 h</td><td></td><td>~90 h</td><td></td><td>~180 h</td></tr></table> |
6b25f1c7cdf6c06831f15450abfecca20876b090f531da5eed60e2cd23bf115e.png | complex | <table><tr><td rowspan="2"></td><td colspan="10">Group</td></tr><tr><td rowspan="3">Variables</td><td colspan="2">G1: Nordic walking (N=8)</td><td rowspan="3"><i>p</i><sup>a</sup></td><td colspan="2">G2: Water aerobics (N=8)</td><td rowspan="3"><i>p</i><sup>a</sup></td><td colspan="2">G3: Non-exercising (N=8)</td><td rowspan="3"><i>p</i><sup>a</sup></td><td rowspan="3"><i>p</i><sup>b</sup></td></tr><tr><td>Baseline</td><td>Eight weeks</td><td>Baseline</td><td>Eight weeks</td><td>Baseline</td><td>Eight weeks</td></tr><tr><td>RT right (s)</td><td>39.1 ± 10.83</td><td>31.0 ± 10.45</td><td>0.04<sup>*</sup></td><td>32.3 ± 16.82</td><td>33.6 ± 15.10</td><td>0.11</td><td>25.3 ± 9.30</td><td>24.9 ± 9.03</td><td>0.40</td><td>0.08</td></tr><tr><td>RT left (s)</td><td>40.8 ± 5.68</td><td>32.1 ± 9.75</td><td>0.02<sup>*</sup></td><td>29.0 ± 11.01</td><td>31.5 ± 10.93</td><td>0.08</td><td>37.4 ± 7.93</td><td>37.0 ± 5.50</td><td>0.48</td><td>0.07</td></tr><tr><td>VP right</td><td>29.4 ± 6.44</td><td>36.1 ± 10.27</td><td>0.04<sup>*</sup></td><td>25.6 ± 10.34</td><td>31.1 ± 8.41</td><td>0.09</td><td>37.3 ± 12.06</td><td>38.9 ± 12.37</td><td>0.89</td><td>0.24</td></tr><tr><td>VP left</td><td>34.6 ± 9.10</td><td>39.0 ± 6.85</td><td>0.12</td><td>38.1 ± 15.13</td><td>35.0 ± 11.50</td><td>0.09</td><td>34.5 ± 8.96</td><td>33.3 ± 9.10</td><td>0.48</td><td>0.83</td></tr></table> |
469ae084f65d779eab28d4fc99950e6123368838e60d6d4d5a3de828ae208b6f.png | simple | <table><tr><td>Time Series</td><td>Germ layer</td><td>TP#</td><td>Switching#</td><td>Gene#</td><td>%</td><td>Non-Xover</td><td>%</td><td>Xover</td><td>%</td></tr><tr><td>Cerebellar development</td><td>Ectoderm</td><td>12</td><td>48,489</td><td>5433</td><td>21.6</td><td>38,722</td><td>79.9</td><td>9767</td><td>20.1</td></tr><tr><td>Human iPS to neuron (wt) 1</td><td>Ectoderm</td><td>4</td><td>45,069</td><td>6692</td><td>26.5</td><td>41,302</td><td>91.6</td><td>3767</td><td>8.4</td></tr><tr><td>Trachea epithelia differentiation</td><td>Endoderm</td><td>19</td><td>8389</td><td>2458</td><td>9.8</td><td>6112</td><td>72.9</td><td>2277</td><td>27.1</td></tr><tr><td>Adipocyte differentiation</td><td>Mesoderm</td><td>16</td><td>66,087</td><td>5996</td><td>23.8</td><td>57,857</td><td>87.5</td><td>8230</td><td>12.5</td></tr><tr><td>Epithelial to mesenchymal</td><td>Mesoderm</td><td>21</td><td>132,661</td><td>7004</td><td>27.8</td><td>109,252</td><td>82.4</td><td>23,409</td><td>17.6</td></tr><tr><td>BMM TB activation IL13</td><td>Mesoderm</td><td>11</td><td>825</td><td>527</td><td>2.1</td><td>564</td><td>68.4</td><td>261</td><td>31.6</td></tr><tr><td>AoSMC response to IL1b</td><td>Mesoderm</td><td>10</td><td>192</td><td>159</td><td>0.6</td><td>129</td><td>67.2</td><td>63</td><td>32.8</td></tr><tr><td>Macrophage response to LPS</td><td>Mesoderm</td><td>23</td><td>32,234</td><td>4557</td><td>18.1</td><td>22,239</td><td>69.0</td><td>9995</td><td>31.0</td></tr><tr><td>ES to cardiomyocyte</td><td>Mesoderm</td><td>13</td><td>189</td><td>163</td><td>0.6</td><td>100</td><td>52.9</td><td>89</td><td>47.1</td></tr><tr><td>Myoblast to myotube</td><td>Mesoderm</td><td>9</td><td>21,912</td><td>4249</td><td>16.9</td><td>18,735</td><td>85.5</td><td>3177</td><td>14.5</td></tr></table> |
d873417b3ead39b1aa6b0d07051d30d1bcb258ae2efad73f619e7a035260305b.png | complex | <table><tr><td rowspan="2">Variable</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>Hazard ratio</td><td>Confidence interval</td><td><i>p</i>-value</td><td>Hazard ratio</td><td>Confidence interval</td><td><i>p</i>-value</td></tr><tr><td>NKp30, C1D1, LFS</td><td>0.24</td><td>0.099–0.61</td><td>0.002</td><td>0.14</td><td>0.043–0.43</td><td>0.001</td></tr><tr><td>NKp30, C1D1, OS</td><td>0.28</td><td>0.088–0.91</td><td>0.034</td><td>0.17</td><td>0.037–0.78</td><td>0.022</td></tr><tr><td>NKp46, C1D21, LFS</td><td>0.25</td><td>0.10–0.59</td><td>0.001</td><td>0.28</td><td>0.093–0.82</td><td>0.020</td></tr><tr><td>NKp46, C1D21, OS</td><td>0.21</td><td>0.067–0.66</td><td>0.007</td><td>0.22</td><td>0.047–1.05</td><td>0.058</td></tr></table> |
01050a54ad4f06308694376d5de3ff399293ce5368af44a401c885c4044ac527.png | simple | <table><tr><td>Number</td><td>Data Source</td><td>Age/years</td><td>Professional background</td></tr><tr><td>1</td><td>Focus group</td><td>53</td><td>Bereavement counselor</td></tr><tr><td>2</td><td>Focus group</td><td>39</td><td>Communication consultant</td></tr><tr><td>3</td><td>Focus group</td><td>46</td><td>Director & Trainer PR Company</td></tr><tr><td>4</td><td>Focus group</td><td>50</td><td>Dietician</td></tr><tr><td>5</td><td>Focus group</td><td>47</td><td>Fitness trainer</td></tr><tr><td>6</td><td>Focus group</td><td>36</td><td>General practitioner</td></tr><tr><td>7</td><td>Focus group</td><td>45</td><td>Social worker</td></tr><tr><td>8</td><td>Assignment</td><td>55</td><td>Facilitator in development sector</td></tr><tr><td>9</td><td>Assignment</td><td>55</td><td>Physiotherapist</td></tr><tr><td>10</td><td>Assignment</td><td>69</td><td>Counselor</td></tr><tr><td>11</td><td>Assignment</td><td>39</td><td>Communication consultant</td></tr><tr><td>12</td><td>Assignment</td><td>61</td><td>Nurse practitioner/Health coach</td></tr><tr><td>13</td><td>Assignment</td><td>55</td><td>Executive coach</td></tr><tr><td>14</td><td>Assignment</td><td>44</td><td>Clinical psychologist</td></tr><tr><td>15</td><td>Assignment</td><td>36</td><td>General practitioner</td></tr><tr><td>16</td><td>Assignment</td><td>54</td><td>General practitioner</td></tr><tr><td>17</td><td>Assignment</td><td>42</td><td>Social Worker</td></tr></table> |
e70fba0d20246b245a046a5f3456bc2d2f6f5aef7f4b90a0bd8aab97c01c3bbf.png | simple | <table><tr><td>Characteristic</td><td>Training set</td><td>Testing set</td><td>Total</td></tr><tr><td>Age</td><td></td><td></td><td></td></tr><tr><td> Median</td><td>59</td><td>58</td><td>59</td></tr><tr><td> Range</td><td>38∼85</td><td>30∼87</td><td>30∼87</td></tr><tr><td>Clinical stage</td><td></td><td></td><td></td></tr><tr><td> Stage I</td><td>0</td><td>0</td><td>0</td></tr><tr><td> Stage II</td><td>8</td><td>13</td><td>21</td></tr><tr><td> Stage III</td><td>163</td><td>158</td><td>321</td></tr><tr><td> Stage IV</td><td>31</td><td>31</td><td>62</td></tr><tr><td>Vital status</td><td></td><td></td><td></td></tr><tr><td> Living</td><td>91</td><td>88</td><td>179</td></tr><tr><td> Dead</td><td>112</td><td>116</td><td>228</td></tr></table> |
d1c3c36dc9da54d39f3d910b5568cbf349d12149f3ce6c206f04de266ed5d41b.png | simple | <table><tr><td> </td><td>All cases (n)</td><td>Fatality (n)</td><td>CFR(95%CI) (%)</td><td>RSE (%)</td></tr><tr><td>Pre-intervention period</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>(Eclampsia patients)</td><td>1233</td><td>258</td><td>20.9(18.7, 23.2)</td><td>5.5</td></tr><tr><td>Intervention period</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>(Eclampsia patients)</td><td>996</td><td>23</td><td>2.3(1.4, 3.2)</td><td>20.9</td></tr></table> |
1a71b69116330ec571a50f0fdb2545b7aee004a9e1aba2cd552665d43182243b.png | simple | <table><tr><td>Certified Reference Materials</td><td>DON Immunosensor (ppm)</td><td>ELISA (ppm)</td><td>Vendor (ppm)</td></tr><tr><td>Wheat</td><td>0.3</td><td>0.2</td><td>0.71</td></tr><tr><td>Corn</td><td>0.92</td><td>1.1</td><td>1.88</td></tr><tr><td>Roasted coffee</td><td>0.19</td><td>0.24</td><td>0.77</td></tr></table> |
348affe26dfd0ee8fd517bb2c8c9b3d1edda2164203494f7b9df62853307e5ce.png | complex | <table><tr><td rowspan="2">Genetic comparison</td><td rowspan="2">Overall and subgroup analysis</td><td rowspan="2">No. of studies</td><td colspan="2">Heterogeneity</td><td rowspan="2">Model</td><td colspan="2">Meta-analysis</td></tr><tr><td>p</td><td><i>I</i><sup>2</sup>(%)</td><td>OR(95%CI)</td><td>p</td></tr><tr><td>T vs. C</td><td>Overall</td><td>8</td><td>0.78</td><td>0.00</td><td>Fixed</td><td>0.92(0.81-1.12)</td><td>0.57</td></tr><tr><td></td><td>AgP</td><td>3</td><td>0.52</td><td>0.00</td><td>Fixed</td><td>0.92(0.71-1.20)</td><td>0.55</td></tr><tr><td></td><td>CP</td><td>5</td><td>0.63</td><td>0.00</td><td>Fixed</td><td>0.97(0.80-1.19)</td><td>0.79</td></tr><tr><td></td><td>Asian</td><td>5</td><td>0.68</td><td>0.00</td><td>Fixed</td><td>0.97(0.80-1.16)</td><td>0.71</td></tr><tr><td></td><td>Jordanian</td><td>2</td><td>0.31</td><td>3.82</td><td>Fixed</td><td>0.85(0.59-1.23)</td><td>0.40</td></tr><tr><td></td><td>Italian</td><td>1</td><td>1.00</td><td>0.00</td><td>Fixed</td><td>1.11(0.64-1.92)</td><td>0.70</td></tr><tr><td></td><td>Mixed</td><td>3</td><td>0.34</td><td>8.52</td><td>Fixed</td><td>0.98(0.76-1.28)</td><td>0.90</td></tr><tr><td></td><td>None</td><td>4</td><td>0.72</td><td>0.00</td><td>Fixed</td><td>0.91(0.74-1.13)</td><td>0.42</td></tr><tr><td>TT vs. CC</td><td>Overall</td><td>6</td><td>0.33</td><td>13.32</td><td>Fixed</td><td>1.22(0.80-1.87)</td><td>0.36</td></tr><tr><td></td><td>AgP</td><td>2</td><td>0.50</td><td>0.00</td><td>Fixed</td><td>1.74(0.88-3.45)</td><td>0.11</td></tr><tr><td></td><td>CP</td><td>4</td><td>0.31</td><td>17.10</td><td>Fixed</td><td>0.98(0.57-1.68)</td><td>0.93</td></tr><tr><td></td><td>Asian</td><td>4</td><td>0.72</td><td>0.00</td><td>Fixed</td><td>0.84(0.48-1.45)</td><td>0.52</td></tr><tr><td></td><td>Jordanian</td><td>2</td><td>0.95</td><td>0.00</td><td>Fixed</td><td>2.10(1.09-4.07)</td><td>0.03</td></tr><tr><td></td><td>Mixed</td><td>3</td><td>0.15</td><td>47.51</td><td>Fixed</td><td>1.39(0.83-2.31)</td><td>0.21</td></tr><tr><td></td><td>None</td><td>3</td><td>0.55</td><td>0.00</td><td>Fixed</td><td>0.92(0.43-1.97)</td><td>0.84</td></tr><tr><td>CT vs. CC</td><td>Overall</td><td>6</td><td>0.80</td><td>0.00</td><td>Fixed</td><td>0.92(0.69-1.23)</td><td>0.58</td></tr><tr><td></td><td>AgP</td><td>2</td><td>0.33</td><td>0.00</td><td>Fixed</td><td>0.74(0.46-1.20)</td><td>0.22</td></tr><tr><td></td><td>CP</td><td>4</td><td>0.98</td><td>0.00</td><td>Fixed</td><td>1.05(0.72-1.52)</td><td>0.80</td></tr><tr><td></td><td>Asian</td><td>4</td><td>0.56</td><td>0.00</td><td>Fixed</td><td>0.87(0.60-1.28)</td><td>0.49</td></tr><tr><td></td><td>Jordanian</td><td>2</td><td>0.72</td><td>0.00</td><td>Fixed</td><td>0.99(0.63-1.55)</td><td>0.96</td></tr><tr><td></td><td>Mixed</td><td>3</td><td>0.93</td><td>0.00</td><td>Fixed</td><td>1.00(0.69-1.45)</td><td>1.00</td></tr><tr><td></td><td>None</td><td>3</td><td>0.43</td><td>0.00</td><td>Fixed</td><td>0.81(0.50-1.29)</td><td>0.37</td></tr><tr><td>TT vs. (CC+CT)</td><td>Overall</td><td>6</td><td>0.15</td><td>38.91</td><td>Fixed</td><td>1.19(0.81-1.74)</td><td>0.37</td></tr><tr><td></td><td>AgP</td><td>2</td><td>0.67</td><td>0.00</td><td>Fixed</td><td>1.98(1.04-3.80)</td><td>0.04</td></tr><tr><td></td><td>CP</td><td>4</td><td>0.22</td><td>32.14</td><td>Fixed</td><td>0.92(0.57-1.46)</td><td>0.71</td></tr><tr><td></td><td>Asian</td><td>4</td><td>0.41</td><td>0.00</td><td>Fixed</td><td>0.84(0.52-1.36)</td><td>0.49</td></tr><tr><td></td><td>Jordanian</td><td>2</td><td>0.84</td><td>0.00</td><td>Fixed</td><td>2.11(1.14-3.91)</td><td>0.02</td></tr><tr><td></td><td>Mixed</td><td>3</td><td>0.06</td><td>63.53</td><td>Random</td><td>1.40(0.66-2.99)</td><td>0.38</td></tr><tr><td></td><td>None</td><td>3</td><td>0.29</td><td>18.41</td><td>Fixed</td><td>1.02(0.49-2.10)</td><td>0.96</td></tr><tr><td>(TT+CT) vs. CC</td><td>Overall</td><td>6</td><td>0.04</td><td>57.80</td><td>Random</td><td>0.66(0.44-1.01)</td><td>0.06</td></tr><tr><td></td><td>AgP</td><td>2</td><td>0.27</td><td>18.76</td><td>Fixed</td><td>0.45(0.30-0.68)</td><td><0.01</td></tr><tr><td></td><td>CP</td><td>4</td><td>0.16</td><td>41.19</td><td>Fixed</td><td>0.86(0.60-1.22)</td><td>0.39</td></tr><tr><td></td><td>Asian</td><td>4</td><td>0.09</td><td>54.35</td><td>Random</td><td>0.59(0.34-1.01)</td><td>0.05</td></tr><tr><td></td><td>Jordanian</td><td>2</td><td>0.05</td><td>72.43</td><td>Random</td><td>0.82(0.37-1.81)</td><td>0.62</td></tr><tr><td></td><td>Mixed</td><td>3</td><td>0.14</td><td>49.45</td><td>Fixed</td><td>0.83(0.59-1.18)</td><td>0.30</td></tr><tr><td></td><td>None</td><td>3</td><td>0.21</td><td>35.43</td><td>Fixed</td><td>0.45(0.29-0.69)</td><td><0.01</td></tr></table> |
e52b4fa8a78e0579a9943764fce6ca32ccf79104cf273baecdd47a22213bdfa4.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">Confidence ratings at end of module (N≥294)</td><td colspan="2">Confidence ratings 3–6 Months after completion (N≥106)</td></tr><tr><td>Mean<sup>1</sup></td><td>%<sup>2</sup></td><td>Mean<sup>1</sup></td><td>%<sup>2</sup></td></tr><tr><td>Respondent’s Confidence in his or her ability to:</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>(a) diagnose depression</td><td>1.23</td><td>99.7</td><td>1.19</td><td>100</td></tr><tr><td>(b) screen for addictions</td><td>1.74</td><td>92.4</td><td>1.67</td><td>94.5</td></tr><tr><td>(c) screen for other mental health conditions</td><td>1.83</td><td>91.8</td><td>1.73</td><td>96.3</td></tr><tr><td>(d) treat depression</td><td>1.43</td><td>99.0</td><td>1.28</td><td>100</td></tr><tr><td>(e) treat other mental health disorders</td><td>1.99</td><td>85.2</td><td>1.93</td><td>87.2</td></tr><tr><td>(f) prescribe medications for mental health conditions</td><td>1.67</td><td>95.0</td><td>1.61</td><td>95.5</td></tr><tr><td>(g) assess patients’ problems and strengths</td><td>1.79</td><td>91.0</td><td>1.66</td><td>92.7</td></tr><tr><td>(h) develop systematized care plans for patients where a mental health care plan is not appropriate</td><td>2.07</td><td>77.5</td><td>1.86</td><td>84.0</td></tr><tr><td>(i) create a mental health care plan fitting Medical Service Plan [provincial program] guidelines</td><td>1.87</td><td>83.4</td><td>1.69</td><td>89.8</td></tr><tr><td>(j) engage mental health patients in a range of interventions (e.g., cognitive behavioural and interpersonal skills training)</td><td>1.97</td><td>81.4</td><td>1.90</td><td>82.6</td></tr><tr><td>(k) offer and coach the Antidepressant Skills Workbook</td><td>1.95</td><td>80.2</td><td>1.83</td><td>85.0</td></tr><tr><td>(l) offer and support the Bounce Back program</td><td>1.54</td><td>92.1</td><td>1.56</td><td>91.7</td></tr><tr><td>(m) In general, how confident are you in the quality of mental health care you provide to your patients?</td><td>1.71</td><td>96.3</td><td>1.46</td><td>99.1</td></tr><tr><td colspan="5">Respondent’s confidence in her or his knowledge/awareness of:</td></tr><tr><td>(a) non-pharmacological interventions (cognitive behavioral skills such as activation, relaxation, negative thinking)</td><td>1.90</td><td>86.8</td><td>1.76</td><td>91.7</td></tr><tr><td>(b) regional mental health resources for mental health patients</td><td>2.05</td><td>82.8</td><td>1.87</td><td>88.1</td></tr></table> |
c180297af1bebbffd210c0a0dc496422cb4894be95afa4cb77e255eb187a47ea.png | simple | <table><tr><td>Reaction</td><td>Genes</td><td>Primer names</td><td>Forward primer sequence</td><td>Reverse primer sequence</td><td>Size (bp)</td></tr><tr><td></td><td><i>hsp60 </i>(groEL_1)</td><td>hsp3/hsp4</td><td>GACCGCCAGTTAAGATAGCG</td><td>TCTCTAGCTACTTCGCAACAAATCC</td><td>297</td></tr><tr><td>1</td><td>CTL0626</td><td>CTL06265'F/CTL06265'R</td><td>GCACACCATCACTATCAC</td><td>GCGCTTGCTTGAGATTTC</td><td>226</td></tr><tr><td>2</td><td>CTL0627</td><td>CTL06275'F/CTL06275'R</td><td>GTTGGCGAGTCCGATGATG</td><td>GACTTCTAATACAGCACCATGTTTG</td><td>195</td></tr><tr><td>3</td><td>CTL0628</td><td>CTL06285'F/CTL06285'R</td><td>GAAACGGTCTCCTACTAGC</td><td>GGTGGGAAGAAATAGTTAAGG</td><td>357</td></tr></table> |
c63606829cd22c3a823a105695f400e0582200039eb132ca9cae7a96f3a60561.png | simple | <table><tr><td>Impact factors</td><td><i>P</i>-value</td><td>Impact factors</td><td><i>P</i>-value</td></tr><tr><td>Epidemiologic information</td><td></td><td>Chemotherapy detail</td><td></td></tr><tr><td>Age at diagnosis</td><td>0.335</td><td>PEB/PVB</td><td>0.043</td></tr><tr><td>Ethnic group</td><td>0.856</td><td>Bleomycin/pingyangmycin</td><td>0.755</td></tr><tr><td>Individual history</td><td></td><td>Weekly/monthly</td><td>0.031</td></tr><tr><td>Prior lung disease</td><td>1.000</td><td>Route of administration</td><td>0.041</td></tr><tr><td>Allergic history</td><td>0.603</td><td>Cumulative dose</td><td>0.000</td></tr><tr><td>Disease state</td><td></td><td>Average course interval</td><td>0.256</td></tr><tr><td>Stage of disease</td><td>0.081</td><td>Combined treatment</td><td></td></tr><tr><td>Histological subtype</td><td>0.741</td><td>G-CSF</td><td>0.331</td></tr><tr><td>Side effects of treatment</td><td></td><td>Antibiotics</td><td>0.904</td></tr><tr><td>Renal dysfunction</td><td>0.001</td><td>Blood transfusion</td><td>-</td></tr><tr><td>Drug allergy</td><td>0.332</td><td>Erythrocyte</td><td>0.116</td></tr><tr><td>Granulopenia</td><td>0.176</td><td>Thrombocyte</td><td>0.035</td></tr><tr><td>Anemia</td><td>0.041</td><td>Chalybeate</td><td>0.067</td></tr><tr><td>Thrombocytopenia</td><td>0.000</td><td>Post-chemotherapy surgery</td><td>0.072</td></tr></table> |
f98340786ad83fd873511812107c3fa770b58fdeec10057025cacc4e077f6561.png | simple | <table><tr><td>>Stage of development</td><td>>WT versus AS</td><td>>WT versus OE</td></tr><tr><td>Immature green</td><td>234</td><td>333</td></tr><tr><td>Mature green</td><td>68</td><td>112</td></tr><tr><td>Red ripe</td><td>105</td><td>332</td></tr><tr><td>Total</td><td>407</td><td>777</td></tr></table> |
8fe792290d4fd43a0fe5417a37522e94475b59aab3cd821d16875a5d9e9ecbee.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">All digital ulcers</td><td colspan="3">Fingertip digital ulcers</td><td colspan="3">Extensor digital ulcers</td></tr><tr><td>GTN</td><td>PBO</td><td>Comparison</td><td>GTN</td><td>PBO</td><td>Comparison</td><td>GTN</td><td>PBO</td><td>Comparison</td></tr><tr><td colspan="10">DUCore</td></tr><tr><td>AUC (arbitrary perfusion units)</td><td>26,245.42 (19,829.5)</td><td>23,973.97 (18,607.44)</td><td>1.2 (1.0 to 1.6)</td><td>18,453.6 (10,721.8)</td><td>16,506.8 (12,498.3)</td><td>1.3 (0.7 to 2.2)</td><td>32,924.1 (24,038.9)</td><td>29,574.3 (21,161.2)</td><td>1.2 (1.0 to 1.6)</td></tr><tr><td>Peak perfusion/baseline perfusion (ratio)</td><td>2.5 (1.4)</td><td>1.9 (0.9)</td><td>1.2 (1.0 to 1.5)</td><td>2.7 (1.7)</td><td>2.1 (0.8)</td><td>1.2 (0.8 to 1.9)</td><td>2.3 (1.2)</td><td>1.8 (1.0)</td><td>1.2 (1.0 to 1.6)</td></tr><tr><td colspan="10">

</td></tr><tr><td colspan="10">DUPeriphery</td></tr><tr><td>AUC (arbitrary perfusion units)</td><td>62,025.2 (41,910.7)</td><td>52,185.4 (33,734.3)</td><td>1.1 (0.8 to 1.6)</td><td>51,939.1 (42,923.2)</td><td>49,019.0 (32,584.1)</td><td>0.9 (0.4 to 2.0)</td><td>70,670.4 (42,293.6)</td><td>54,560.3 (36,606.2)</td><td>1.4 (1.1 to 1.7)</td></tr><tr><td>Peak perfusion/baseline perfusion (ratio)</td><td>2.2 (1.5)</td><td>2.1 (1.4)</td><td>1.0 (0.9 to 1.2)</td><td>2.4 (2.2)</td><td>2.5 (2.1)</td><td>0.9 (0.7 to 1.2)</td><td>2.0 (0.7)</td><td>1.8 (0.8)</td><td>1.1 (1.0 to 1.4)</td></tr></table> |
a3f379eb37d52fc50f105aa6918da068b00f70009222196696e1b21abe3fa7b1.png | simple | <table><tr><td>No.</td><td>shRNA Targets of <i>RB1</i></td></tr><tr><td>siRNA-RB1-2</td><td>GGGUUGUGUCGAAAUUGGATT</td></tr><tr><td>siRNA-RB1-4</td><td>GGAGUAUGAUUCUAUUAUATT</td></tr><tr><td>Negative control siRNA (NC siRNA)</td><td>UUCUCCGAACGUGUCACGUTT</td></tr></table> |
3b1e3cb3acafeff44163cec372af81e4755643a39e1e2349c9b2050e9d6dea42.png | complex | <table><tr><td colspan="2">Module I: Basic concepts in global health</td></tr><tr><td>01.</td><td>Defining and measuring global health</td></tr><tr><td>02.</td><td>Global health definitions, case studies</td></tr><tr><td>03.</td><td>Historical origin and evolution</td></tr><tr><td>04.</td><td>Health systems and global health</td></tr><tr><td colspan="2">Module II: Understanding the key global health challenges</td></tr><tr><td>01.</td><td>Current global health status</td></tr><tr><td>02.</td><td>Global burden of disease</td></tr><tr><td>03.</td><td>Global health priorities for twenty-first century</td></tr><tr><td>04.</td><td>Global health at the human–animal–ecosystem interface</td></tr><tr><td colspan="2">Module III: Cross-cutting themes in global health and emerging trends</td></tr><tr><td>01.</td><td>Environment, climate, and migration</td></tr><tr><td>02.</td><td>Food, water, and sanitation</td></tr><tr><td>03.</td><td>Health disparities</td></tr><tr><td>04.</td><td>Women’s health</td></tr><tr><td>05.</td><td>Emerging, remerging infectious diseases</td></tr><tr><td>06.</td><td>NCD and injuries</td></tr><tr><td>07.</td><td>Maternal and child health</td></tr><tr><td>08.</td><td>Childhood immunization</td></tr><tr><td>09.</td><td>Adolescent health</td></tr><tr><td>10.</td><td>Neglected tropical diseases</td></tr><tr><td>11.</td><td>Antimicrobial resistance</td></tr><tr><td colspan="2">Module IV: Global health diplomacy</td></tr><tr><td>01.</td><td>Overview of global health diplomacy</td></tr><tr><td>02.</td><td>Global health actors and activities</td></tr><tr><td>03.</td><td>Global health financing</td></tr><tr><td>04.</td><td>Global health policy and governance</td></tr><tr><td>05.</td><td>Drivers of policy for global health diplomacy</td></tr><tr><td>06.</td><td>Globalization, trade, work, and health</td></tr><tr><td>07.</td><td>Foreign policy and health</td></tr><tr><td colspan="2">Module V: Global health security</td></tr><tr><td>01.</td><td>Global health security</td></tr><tr><td>02.</td><td>Pandemics and health security responses</td></tr><tr><td>03.</td><td>Health in complex humanitarian emergencies</td></tr><tr><td>04.</td><td>Humanitarian response and humanitarian dilemmas</td></tr><tr><td>05.</td><td>Global health equity</td></tr><tr><td>06.</td><td>Values in global health</td></tr><tr><td>07.</td><td>Toward a social justice approach to global health</td></tr><tr><td colspan="2">Module VI: Research, development, innovation, and technology for global health</td></tr><tr><td>01.</td><td>The environment, sustainable development, and health</td></tr><tr><td>02.</td><td>Universal health coverage in the context of aging</td></tr><tr><td>03.</td><td>Sustaining good health with equity at low cost</td></tr><tr><td>04.</td><td>Science and technology for global health</td></tr><tr><td>05.</td><td>Scaling up effective models in global health delivery</td></tr></table> |
a20bfab51027eaab7afca3978d9d1449b587136a636bf4123544814cb6de891b.png | simple | <table><tr><td>Questions</td><td>Partners</td><td>Regenstrief</td><td>Intermountain Health Care</td><td>Veterans' Health Administration</td></tr><tr><td>CIS modules offered (products that have capability to provide decision support)?</td><td>Yes, CPOE, results review, laboratory, outpatient clinical documentation, eMAR, Drug-Drug/Allergy/Lab Interaction checking. BCMA</td><td>Yes, CPOE, consults from specialists. Documentation: patient visit notes, ADT summaries, problem lists. Links to test results, notes</td><td>Yes, Antibiotic, TPN; Results review; RN, RT, Pharmacist charting; Infection & Disease monitoring, ADR triggers, VTE high risk alerts</td><td>Yes, Order menus, sets, quick orders. documentation. Templates. Drug-Drug/Allergy/Lab Interaction checking. BCMA</td></tr><tr><td>EHR delivery model?</td><td>Onsite</td><td>Onsite</td><td>Onsite (Server and web based)</td><td>Onsite (move to regional server)</td></tr><tr><td>CDS content implemented/configured/maintained by customer or vendor?</td><td>maintained by informaticians. Most content separate from code viewed thru repository</td><td>Clinician/Informaticians update terminology and decision support rules as needed</td><td>Users responsible for content. Programmers logic. Updated weekly, larger updates quarterly</td><td>CDS maintained, implemented locally. National releases with local configuration.</td></tr><tr><td>Collect structured data and which controlled vocabularies?</td><td>LOINC, RxNorm, SNOMED, ICD-9, CPT, FDB</td><td>ICD-9 & CPT codes avail. Most entered via Regenstrief Dict. mapped to standard vocabs.</td><td>Mostly coded data, some dictated notes as free text. LOINC, SNOMED, ICD-9</td><td>Not from clinician notes, but reminder templates do. ICD-9 for problem list</td></tr><tr><td>Support ad-hoc queries? Live replicating database?</td><td>Yes. Yes, weekly to monthly depending on data element</td><td>Queries done by data analysts on real database, in response to requests from end users.</td><td>Yes, but most reports run on EDW from programmers. Have some canned reports monthly</td><td>Yes, use replicated DB, varied update frequency; ProClarity data cubes</td></tr><tr><td>HL7 InfoButton?</td><td>Yes</td><td>No</td><td>Yes</td><td>No, but something similar</td></tr><tr><td>Arden Syntax for MLM?</td><td>No</td><td>No. Gopher Care Rules corresponds to Arden Syntax.</td><td>No (some graduate projects)</td><td>No</td></tr><tr><td>Clinical knowledge editor for user to create CDS?</td><td>Yes</td><td>Editor used by infomaticians to create CDS</td><td>Ability for knowledgeable users to create CDS</td><td>Not by end user. Some local configuration by support staff</td></tr><tr><td>Content mgmt system separate from EHR?</td><td>Yes</td><td>No</td><td>Online K repository, most review/updates programmers</td><td>No. Pilots are ongoing.</td></tr><tr><td>Reporting capability to track effect/usage of CDS content?</td><td>Yes</td><td>User responses prospectively, not retrospective</td><td>Yes, from reports in the EDW</td><td>Yes, focused on performance measures not CDS usage</td></tr><tr><td>Drug database supplier?</td><td>FDB</td><td>In-house drug terms</td><td>FDB</td><td>Internal Drug/Allergy files</td></tr><tr><td>3rd party CDS content vendors?</td><td>Thompson Micromedex, UpToDate</td><td>No</td><td>MicroMedex through Info-buttons</td><td>MicroMedex, UpToDate, etc. at point of care</td></tr><tr><td>Provide clinical content (starter sets). What content is included, how and how often and is it updated?</td><td>CDS content provided and maintained by the Informatics groups. Updates distributed on an as needed basis.</td><td>Alerts, drug-drug. Formulary, price. Order sets. Default drug strengths, frequencies, or instructions. updates mult/yr.</td><td>All alert logic is provided, developed, and maintained by institution. weekly and quarterly updates</td><td>Local development of reminders, order menus, document templates.</td></tr><tr><td>On-line collaborative knowledge development environment web 2.0?</td><td>Yes</td><td>No</td><td>No</td><td>Yes, starting SharePoint sites for national groups</td></tr><tr><td>Internet repository for clients to share locally generated CDS?</td><td>No</td><td>No</td><td>No</td><td>Some networks have web sites to share CDS</td></tr></table> |
e9841c6672802eed33bd5aabf725107fbd0581ecd018bafee085705d640055d3.png | simple | <table><tr><td></td><td>NZ</td><td>BL</td><td>SY</td><td>BK</td><td>WL†</td><td>EB†</td></tr><tr><td>NZ</td><td>-</td><td>0.030</td><td><underline>0.001</underline></td><td><underline>0.015</underline></td><td>0.074</td><td>0.096</td></tr><tr><td>BL</td><td>0.014</td><td>-</td><td>0.038</td><td>0.030</td><td>0.061</td><td>0.104</td></tr><tr><td>SY</td><td>0.042</td><td>0.053</td><td>-</td><td><underline>0.015</underline></td><td>0.099</td><td>0.105</td></tr><tr><td>BK</td><td>0.038</td><td>0.070</td><td>0.033</td><td>-</td><td>0.096</td><td>0.111</td></tr><tr><td>WL†</td><td>0.048</td><td>0.047</td><td>0.079</td><td>0.080</td><td>-</td><td>0.033</td></tr><tr><td>EB†</td><td>0.078</td><td>0.105</td><td>0.067</td><td>0.057</td><td>0.054</td><td>-</td></tr></table> |
4332318ebeb1851f7015308d05307ba5602b5f8b2522a3037b8f3b57be165298.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">H3K27me3</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>Low</td><td>High</td><td>Total</td></tr><tr><td>pS9-GSK3β</td><td></td><td></td><td></td><td></td></tr><tr><td> Low</td><td>13</td><td>10</td><td>23</td><td></td></tr><tr><td> High</td><td>23</td><td>64</td><td>87</td><td></td></tr><tr><td> Total</td><td>36</td><td>74</td><td>110</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>0.006</td></tr></table> |
74f53837c5b37eaf502dc6eb580051e1a8fc28a4a65c8bb29c46fa6fd89b5290.png | complex | <table><tr><td></td><td></td><td colspan="2">AS Genome</td><td colspan="2">AM Genome</td></tr><tr><td>Chromosome</td><td>Length, bp</td><td>Change (SNPs)</td><td>Change Rate</td><td>Change (SNPs)</td><td>Change Rate</td></tr><tr><td>1</td><td>66,776,104</td><td>391</td><td>170,783</td><td>404</td><td>165,287</td></tr><tr><td>2</td><td>44,510,304</td><td>258</td><td>172,521</td><td>250</td><td>178,041</td></tr><tr><td>3</td><td>48,258,781</td><td>208</td><td>232,013</td><td>204</td><td>236,563</td></tr><tr><td>4</td><td>43,347,107</td><td>176</td><td>246,290</td><td>195</td><td>222,293</td></tr><tr><td>5</td><td>37,320,184</td><td>190</td><td>196,422</td><td>200</td><td>186,601</td></tr><tr><td>6</td><td>28,216,978</td><td>76</td><td>371,276</td><td>86</td><td>328,104</td></tr><tr><td>Unmapped</td><td>32,912,371</td><td>148</td><td>222,381</td><td>151</td><td>217,963</td></tr><tr><td>Total</td><td>301,341,829</td><td>1447</td><td>208,253</td><td>1490</td><td>202,243</td></tr></table> |
b4bb280ac8e0bb558aff942a4fb63bf665604f42342d5470938ca990c8fc4203.png | simple | <table><tr><td></td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Waist Circumference (abnormal versus normal)</td><td>1.697 (1.305–2.207)</td><td>1.712 (1.308–2.242)</td><td>1.40 (1.02–1.91)</td></tr><tr><td>Body Mass Index (abnormal versus normal)</td><td>1.901 (1.347–2.680)</td><td>1.941 (1.367–2.754)</td><td>—</td></tr><tr><td>% Body Fat (abnormal versus normal)</td><td>1.398 (1.044–1.872)</td><td>1.436 (1.068–1.930)</td><td>1.24 (0.90–1.71)</td></tr><tr><td>Muscle Mass Index (abnormal versus normal)</td><td>1.113 (0.788–1.572)</td><td>1.190 (0.836–1.692)</td><td>1.42 (0.90–2.07)</td></tr></table> |
130654ee2ce5f8dd34a36fc2c864cbef2f6b879b2f238de4e61c7834939af364.png | simple | <table><tr><td>Humans and Great Apes</td><td>All other mammals e.g. mouse</td><td>Peptide abbreviation</td><td>Gene name</td></tr><tr><td>Relaxin-1</td><td>Relaxin<sup>#</sup></td><td>RLX1</td><td><i>RLN1</i></td></tr><tr><td>Relaxin-2<sup>#</sup></td><td></td><td>RLX2</td><td><i>RLN2</i></td></tr><tr><td>Relaxin-3</td><td>Relaxin-3</td><td>RLX3</td><td><i>RLN3</i></td></tr></table> |
87ec1cbf7e8ac1ddb816e52e0c41066a642ec5e8e7f93c3b30290ff6b6cea2a5.png | simple | <table><tr><td>Identifier</td><td>Best Arabidopsis match</td><td>Possible function</td><td>Position (kb)</td><td>Gene ID</td></tr><tr><td><i>C2H2 TF</i></td><td>AT3G18290</td><td>RING finger and CHY zinc finger encoding BRUTUS (BTS), E3 ligase protein with metal ion binding and DNA binding domains, which negatively regulates the response to iron deficiency</td><td>1,000</td><td>MDP0000283750</td></tr><tr><td><i>C2H2 TF</i></td><td>AT1G68360</td><td>C2H2 and C2HC zinc finger family</td><td>1,020</td><td>MPD0000183099</td></tr><tr><td><i>MdMYB7</i></td><td>AT1G68320</td><td>MYB involved in regulation of phosphate starvation responses and gibberellic acid biosynthesis.</td><td>1,070</td><td>MDP0000659260</td></tr><tr><td><i>bHLH</i></td><td>AT1G25330</td><td>bHLH75, BR enhanced</td><td>1,080</td><td>MDP0000725991</td></tr><tr><td><i>COL</i></td><td>AT1G68520</td><td>Contans-like light regulation of secondary metabolites</td><td>1,220</td><td>MDP0000185616</td></tr><tr><td><i>bZIP</i></td><td>AT1G68640</td><td>HBP-1b(c1), BZIP - PAN is essential for AG activation in early flowering</td><td>1,380</td><td>MDP0000250967</td></tr><tr><td><i>MdG2L6</i></td><td>AT1G25550</td><td>Golden-like ARR18 MYB-related</td><td>1,440</td><td>MDP0000202657</td></tr><tr><td><i>MdAP2D36 TF</i></td><td>AT1G68840</td><td>Regulator of vac ATPase Rav2 is part of a complex that has been named 'regulator of the (H+)-ATPase of the vacuolar and endosomal membranes' (RAVE)</td><td>1,480</td><td>MDP0000939633</td></tr><tr><td><i>LAR1</i></td><td></td><td>MdLAR1</td><td>1,540</td><td>MDP0000376284</td></tr><tr><td><i>bHLH</i></td><td>AT1G68810</td><td>Known bHLH, no other function</td><td>1,550</td><td>MDP0000319726</td></tr><tr><td><i>bHLH</i></td><td>AT1G68920</td><td>bHLH49 Known bHLH, no other function</td><td>1,890</td><td>MDP0000154272</td></tr><tr><td><i>MdbHLH21</i></td><td>AT1G69010</td><td>BES1-INTERACTING MYC-LIKE PROTEIN 2</td><td>1,970</td><td>MDP0000149222</td></tr></table> |
241558ba26f216d6c6e32bea434f27e8f105eb5647bde7ef4543f406ea771d17.png | complex | <table><tr><td></td><td colspan="2">PCI</td><td></td><td colspan="2">No PCI</td><td></td><td></td></tr><tr><td>Study</td><td>Events</td><td>Total</td><td>Incidence (%)</td><td>Events</td><td>Total</td><td>Incidence (%)</td><td>Weight (%)</td></tr><tr><td>VALG</td><td>7</td><td>136</td><td>5.1</td><td>16</td><td>145</td><td>11.0</td><td>10.5</td></tr><tr><td>MDACC</td><td>2</td><td>46</td><td>4.3</td><td>14</td><td>51</td><td>27.5</td><td>9.0</td></tr><tr><td>RTOG 8403</td><td>8</td><td>93</td><td>8.6</td><td>18</td><td>94</td><td>19.1</td><td>12.2</td></tr><tr><td>SWOG</td><td>1</td><td>111</td><td>0.9</td><td>13</td><td>115</td><td>11.3</td><td>8.7</td></tr><tr><td>RTOG 0214</td><td>13</td><td>163</td><td>8.0</td><td>32</td><td>177</td><td>18.1</td><td>20.9</td></tr><tr><td>Li</td><td>10</td><td>81</td><td>12.3</td><td>29</td><td>75</td><td>38.7</td><td>20.5</td></tr><tr><td>NVALT-11</td><td>7</td><td>87</td><td>8.0</td><td>27</td><td>88</td><td>30.7</td><td>18.3</td></tr><tr><td>Total</td><td>48</td><td>717</td><td></td><td>149</td><td>745</td><td></td><td></td></tr></table> |
a18ad8121e727e9f5677515625e75af183bbe0d8a90300733ad75b1191956e5b.png | simple | <table><tr><td></td><td>Placebo(n = 62)</td><td>30 mg/d LDX(n = 119)</td><td>50 mg/d LDX(n = 116)</td><td>70 mg/d LDX(n = 121)</td><td>All LDX Doses(n = 356)</td></tr><tr><td>Baseline[Mean (SD)]</td><td>6.9(1.34)</td><td>7.4(1.69)</td><td>7.4(1.51)</td><td>7.2(1.42)</td><td>7.3(1.54)</td></tr><tr><td>Endpoint[Mean (SD)]</td><td>7.0(1.33)</td><td>7.2(1.21)</td><td>7.0(1.44)</td><td>7.0(1.61)</td><td>7.1(1.43)</td></tr><tr><td>Change[LS Mean (SE)]</td><td>-0.1(0.15)</td><td>-0.1(0.11)</td><td>-0.3(0.11)</td><td>-0.2(0.11)</td><td>-0.2(0.07)</td></tr></table> |
800d4679934d00e757078d742e1815075cc00e875d34c3992f3400d70e21cf86.png | simple | <table><tr><td>Week</td><td>Weekly theme</td></tr><tr><td>1</td><td>Introduction and briefing on the aims of the rehabilitation program• Introduction to group• Introduction of the concept of self-efficacy• Information on post-stroke balance self-efficacy and rehabilitation</td></tr><tr><td>2</td><td>Understanding the relationships between thoughts, emotions, and behavior• Introduction to the CBT model• Understanding fear, fear of falling, fall risks, and actual falls• Understanding the automatic thoughts and emotional and behavioral reflection associated with fear of falling</td></tr><tr><td>3</td><td>Exploring thoughts and maladaptive responses• Identifying maladaptive thoughts leading to physical inactivity• Adapting realistic views of fall risk and the consequences of falls• Recognizing risky behavior• Overcoming barriers to physical activity</td></tr><tr><td>4</td><td>Exploring adaptive thoughts and behavioral responses• Fall prevention strategies and safety issues• Recognizing and minimizing fall risk</td></tr><tr><td>5</td><td>Implementing and reviewing behavioral changes related to ADL• Setting personal goals for ADL• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety</td></tr><tr><td>6</td><td>Implementing and reviewing behavioral changes related to social activities• Setting personal goals for social activities• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety</td></tr><tr><td>7</td><td>Reviewing and advancing individual therapeutic goals• Reviewing personal goals for ADL and social activities• Establishing a regular exercise plan</td></tr><tr><td>8</td><td>Consolidating the experiences of the rehabilitation program• Sharing attitudes and experiences of fear of falling before and after the group• Sharing experiences of applying cognitive-restructuring skills• Establishing the long-term personal goals of regular exercise, ADL independence, and social engagement</td></tr></table> |
d748a8bc7e4b428d98921bdca9f8b3a11c0700ecd6cabc45b76ad66daa54ea2e.png | complex | <table><tr><td></td><td>Athletes</td><td>Controls</td><td><i>P</i>‐values</td></tr><tr><td colspan="4">Baseline characteristics</td></tr><tr><td><i>n</i></td><td>19</td><td>8</td><td></td></tr><tr><td>Age (year)</td><td>26 ± 5</td><td>31 ± 4</td><td>0.07</td></tr><tr><td>Height (m)</td><td>1.77 ± 0.08</td><td>1.80 ± 0.10</td><td>0.47</td></tr><tr><td>Body mass (kg)</td><td>72.6 ± 9.5</td><td>84.1 ± 12.2</td><td>0.02</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>23 ± 2</td><td>26 ± 3</td><td>0.01</td></tr><tr><td>Maximal oxygen uptake (mL/kg·min<sup>−1</sup>)</td><td>55.9 ± 4.9</td><td>39.2 ± 5.0</td><td><0.001</td></tr><tr><td colspan="4">Resting values</td></tr><tr><td><i>n</i></td><td>19</td><td>8</td><td></td></tr><tr><td>Heart rate (bpm)</td><td>54 ± 8</td><td>58 ± 5</td><td>0.20</td></tr><tr><td>Mean arterial pressure (mmHg)</td><td>73 ± 10</td><td>74 ± 10</td><td>0.92</td></tr><tr><td>Middle cerebral artery mean blood velocity (cm/sec)</td><td>63.9 ± 11.7</td><td>65.5 ± 14.8</td><td>0.75</td></tr><tr><td>Cerebrovascular conductance index (cm sec<sup>−1</sup> mmHg<sup>−1</sup>)</td><td>0.88 ± 0.14</td><td>0.91 ± 0.23</td><td>0.72</td></tr></table> |
1053c1b6363fcc2af139c7314f7036e005e479bcf7d483dba164ffb48da01de6.png | complex | <table><tr><td></td><td>Healthy (<i>n</i> = 18)</td><td>Post-OP (<i>n</i> = 28)</td><td>Sepsis (<i>n</i> = 15)</td></tr><tr><td>IL-6 (pg/ml)</td><td>0.0; 0.0–0.8</td><td>216.7; 48.8–360.5</td><td>577.7; 521.9–583.2</td></tr><tr><td rowspan="3"><i>P</i>-value</td><td colspan="3">Healthy versus Post-OP: <i>P</i> < .001***</td></tr><tr><td colspan="3">Healthy versus Sepsis: <i>P</i> < .001***</td></tr><tr><td colspan="3">Post-OP versus Sepsis: <i>P</i> <.001***</td></tr><tr><td>TRX1 (ng/ml)</td><td>11.0; 10.0–12.1</td><td>11.3; 9.6–15.6</td><td>34.0; 19.7–57.7</td></tr><tr><td rowspan="3"><i>P</i>-value</td><td colspan="3">Healthy versus Post-OP: <i>P</i> = .458</td></tr><tr><td colspan="3">Healthy versus Sepsis: <i>P</i> < .001***</td></tr><tr><td colspan="3">Post-OP versus Sepsis: <i>P</i> <.001***</td></tr><tr><td>MIF (pg/ml)</td><td>161.6; 148.5–214.0</td><td>156.4; 115.1–398.7</td><td>1821.1; 412.2–3708</td></tr><tr><td rowspan="3"><i>P</i>-value</td><td colspan="3">Healthy versus Post-OP: <i>P</i> = .954</td></tr><tr><td colspan="3">Healthy versus Sepsis: <i>P</i> = .005**</td></tr><tr><td colspan="3">Post-OP versus Sepsis: <i>P</i> < .001***</td></tr></table> |
6c7d06d1be2db3e85fa021b4f605c47dcdb7e6ef5868ec260b5cf4b6cd184b6b.png | simple | <table><tr><td>No.</td><td>Age</td><td>Sex</td><td>AQP1/4 tissue</td><td>Brief history</td><td>Probable cause/</td></tr><tr><td> </td><td>(years)</td><td> </td><td>immunoreactivity*</td><td> </td><td>underlying cause of</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>CPM</td></tr><tr><td>1</td><td>56</td><td>M</td><td>0</td><td>Alcoholism; nausea and vomiting 1 week; hyponatremia, abnormal liver function tests; presented to Emergency Room in cardiorespiratory arrest.</td><td>Rapid correction of hyponatremia</td></tr><tr><td>2</td><td>53</td><td>M</td><td>0</td><td>Depression and chronic obstructive pulmonary disease. Not seen for 4 days; found dehydrated and malnourished; drug and alcohol screen negative.</td><td>Dehydration, malnutrition and hypernatremia</td></tr><tr><td>3</td><td>33</td><td>M</td><td>0</td><td>Cryptogenic cirrhosis with antitrypsin heterozygosity; orthotopic liver transplant and hyponatremia followed by progressive obtundation and seizures.</td><td>Orthotopic liver transplant</td></tr><tr><td>4</td><td>45</td><td>M</td><td>0</td><td>Small-cell lung carcinoma, metastatic to liver; abnormal liver function tests; possible malnutrition; hyperkalemia; several syncopal episodes in preceding hours; presented with respiratory failure.</td><td>SIAD secondary to small-cell lung carcinoma</td></tr><tr><td>5</td><td>24</td><td>F</td><td>↑</td><td>Hepatic failure and autoimmune thrombocytopenic purpura, 6 months; altered consciousness level and nonconvulsive status epilepticus 5 weeks before death; hypocalcemia, hyperammonemia and elevated liver enzymes.</td><td>Hepatic failure and hypocalcemia</td></tr><tr><td>6</td><td>68</td><td>F</td><td>↑</td><td>Hypertension, obesity, diabetes mellitus, hyperuricemia and remote endometrial carcinoma (treated by resection, chemotherapy, and radiotherapy); presented with gangrene of the right fifth toe; generalized seizure followed by unresponsiveness.</td><td>Diabetes mellitus type II</td></tr></table> |
d1da8022d05e7f0364cd0c78737f441dcf7db58532b1f088aeca114a80d69e18.png | complex | <table><tr><td>Health risk behavior</td><td colspan="2">Men</td><td colspan="2">Women</td></tr><tr><td></td><td>N</td><td>(%)</td><td>N</td><td>(%)</td></tr><tr><td>Current smoking</td><td>10784</td><td>(57.3)</td><td>3099</td><td>(15.6)</td></tr><tr><td>Excess alcohol consumption</td><td>5177</td><td>(27.4)</td><td>1155</td><td>(5.8)</td></tr><tr><td>Physical inactivity</td><td>13989</td><td>(71.2)</td><td>14926</td><td>(72.0)</td></tr><tr><td>Poor dietary habits</td><td>7974</td><td>(40.6)</td><td>5671</td><td>(27.4)</td></tr><tr><td>Stress</td><td>9639</td><td>(51.9)</td><td>12151</td><td>(61.3)</td></tr><tr><td>Non-attendance of health check-ups</td><td>5243</td><td>(27.5)</td><td>8532</td><td>(42.3)</td></tr></table> |
2bdbc72014707ac874252cab2f6e187c01b730cc79bf6b6084e256aa4ce18fa4.png | simple | <table><tr><td></td><td>Time-dependent Burden</td><td>Emotional Burden</td><td>Exisitential Burden</td><td>Physical Burden</td><td>Service-related Burden</td><td>Total Care Burden</td><td>BIC Total</td></tr><tr><td>SF-8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> PF (Physical Functioning)</td><td>-0.36</td><td>-0.35</td><td>-0.40</td><td>-0.52</td><td>-0.26</td><td>-0.44</td><td>-0.52</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td> RP (Role functioning Physical)</td><td>-0.47</td><td>-0.48</td><td>-0.49</td><td>-0.57</td><td>-0.28</td><td>-0.56</td><td>-0.65</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td> BP (Bodily Pain)</td><td>-0.41</td><td>-0.38</td><td>-0.40</td><td>-0.64</td><td>-0.26</td><td>-0.44</td><td>-0.56</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td> GH (General Health perceptions)</td><td>-0.39</td><td>-0.40</td><td>-0.40</td><td>-0.56</td><td>-0.27</td><td>-0.46</td><td>-0.59</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td> VT (Vitality)</td><td>-0.35</td><td>-0.41</td><td>-0.41</td><td>-0.50</td><td>-0.26</td><td>-0.41</td><td>-0.47</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td> SF (Social Functioning)</td><td>-0.59</td><td>-0.48</td><td>-0.49</td><td>-0.54</td><td>-0.31</td><td>-0.57</td><td>-0.62</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td> RE (Role functional Emotional)</td><td>-0.52</td><td>-0.50</td><td>-0.51</td><td>-0.55</td><td>-0.25</td><td>-0.58</td><td>-0.60</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td> MH (Mental Health)</td><td>-0.55</td><td>-0.58</td><td>-0.55</td><td>-0.55</td><td>-0.29</td><td>-0.59</td><td>-0.64</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td>CES-D</td><td>0.49</td><td>0.54</td><td>0.53</td><td>0.48</td><td>0.32</td><td>0.51</td><td>0.62</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr><tr><td>ZBI</td><td>0.76</td><td>0.72</td><td>0.70</td><td>0.68</td><td>0.38</td><td>0.80</td><td>0.84</td></tr><tr><td> p-value</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td><td>0.0001</td></tr></table> |
b2c91eedf3760b95ba9bd3f65e47501cfec3cf5250f7ac7a8434092c8200a1ca.png | simple | <table><tr><td></td><td>Controls (<i>n</i> = 1846)</td><td>Cases (<i>n</i> = 695)</td><td><i>p</i>-Value <sup>2</sup></td></tr><tr><td>Age (years), mean (SD)</td><td>56.1 (9.1)</td><td>56.4 (9.6)</td><td>0.44</td></tr><tr><td>Female, <i>n</i> (%)</td><td>596 (32.3)</td><td>222(31.9)</td><td>0.87</td></tr><tr><td>Family history of colorectal cancer (yes) <sup>1</sup>, <i>n</i> (%)</td><td>99 (5.4)</td><td>58 (8.4)</td><td>0.006</td></tr><tr><td>BMI, <i>n</i> (%)</td><td></td><td></td><td></td></tr><tr><td> <25 kg/m<sup>2</sup></td><td>1225 (66.4)</td><td>476 (68.5)</td><td>0.31</td></tr><tr><td> ≥25 kg/m<sup>2</sup></td><td>621 (33.6)</td><td>219 (31.5)</td><td></td></tr><tr><td>Educational level, <i>n</i> (%)</td><td></td><td></td><td></td></tr><tr><td> <12 years</td><td>282 (15.6)</td><td>252 (36.3)</td><td><0.001</td></tr><tr><td> ≥12 years</td><td>1521 (84.4)</td><td>443 (63.7)</td><td></td></tr><tr><td>Smoking status, <i>n</i> (%)</td><td></td><td></td><td></td></tr><tr><td> Never</td><td>818 (44.3)</td><td>315 (45.3)</td><td>0.65</td></tr><tr><td> Ever</td><td>1028 (55.7)</td><td>380 (54.7))</td><td></td></tr><tr><td>Alcohol consumption, <i>n</i> (%)</td><td></td><td></td><td></td></tr><tr><td> Never</td><td>560 (30.3)</td><td>210 (30.2)</td><td>0.95</td></tr><tr><td> Ever</td><td>1286 (69.7)</td><td>485 (69.8)</td><td></td></tr><tr><td>Regular exercise (yes), <i>n</i> (%)</td><td>1048 (58.2)</td><td>226 (32.5)</td><td><0.001</td></tr><tr><td>Total caloric intake (kcal/day), mean (SD)</td><td>1689.9 (560.4)</td><td>2018.7 (529.7)</td><td><0.001</td></tr><tr><td>CRP (ng/mL), median (IQR)</td><td>101.5 (48.3, 217.3)</td><td>212.6 (88.4, 614.7)</td><td><0.001</td></tr></table> |
536c84c6458a1031d370bc3530c53c37d2d415de2167310ef184886c5a1df049.png | complex | <table><tr><td></td><td></td><td></td><td colspan="2">Microaerobic culture</td><td></td></tr><tr><td></td><td></td><td></td><td>+</td><td>-</td><td>Total</td></tr><tr><td>4.1 <i>Campylobacter coli </i>detection in faecal samples</td><td></td><td>+</td><td>125</td><td>1</td><td>126</td></tr><tr><td></td><td>Real-time PCR</td><td>-</td><td>3</td><td>17</td><td>20</td></tr><tr><td></td><td></td><td>Total</td><td>128</td><td>18</td><td>146</td></tr><tr><td>4.2 <i>Campylobacter coli </i>detection in feed samples</td><td></td><td>+</td><td>21</td><td>1</td><td>22</td></tr><tr><td></td><td>Real-time PCR</td><td>-</td><td>2</td><td>26</td><td>28</td></tr><tr><td></td><td></td><td>Total</td><td>23</td><td>27</td><td>50</td></tr><tr><td>4.3 <i>Campylobacter coli </i>detection in environmental samples</td><td></td><td>+</td><td>34</td><td>2</td><td>36</td></tr><tr><td></td><td>Real-time PCR</td><td>-</td><td>3</td><td>47</td><td>50</td></tr><tr><td></td><td></td><td>Total</td><td>37</td><td>49</td><td>86</td></tr></table> |
7e4ce9946ee017f1c2cf35e5a61b5e253dc038d2dcde994d2f920062e26c5e9f.png | complex | <table><tr><td rowspan="2">Sequences</td><td colspan="2">Descent</td><td colspan="2">Ascent</td><td colspan="2">Stop (Life Bases)</td><td><i>P</i></td></tr><tr><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td></td></tr><tr><td>Feeling pain (FP)</td><td>10</td><td>31.2</td><td>14</td><td>43.8</td><td>8</td><td>25</td><td>0.4633</td></tr><tr><td>Putting meaning to those feelings (PM)</td><td>5</td><td>17.8</td><td>16</td><td>57.2</td><td>7</td><td>25</td><td>0.0269 *</td></tr><tr><td>Adjusting running style (AR)</td><td>6</td><td>40</td><td>7</td><td>46.6</td><td>2</td><td>13.4</td><td>0.3593</td></tr><tr><td>Attempting to overcome the problem (OP)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>7</td><td>100</td><td>0.0009 *</td></tr><tr><td>Influence of other runners (IR)</td><td>0</td><td>0</td><td>5</td><td>23.8</td><td>16</td><td>76.2</td><td>0.0005 *</td></tr><tr><td>Assessing the overall situation (AS)</td><td>3</td><td>10.3</td><td>5</td><td>17.3</td><td>21</td><td>74.4</td><td>0.0005 *</td></tr><tr><td>Total</td><td>24</td><td>18.2</td><td>47</td><td>35.6</td><td>61</td><td>46.2</td><td>0.0003 *</td></tr></table> |
7083736ee80d0eb52577eb8668050fa2068964b062ed9b63437a773f8db36c98.png | complex | <table><tr><td>Characteristics</td><td>Parameter estimate</td><td>Standard error</td><td>Odds ratio (95 % CI)</td><td><i>P</i>-value</td></tr><tr><td colspan="5">Univariate analysis</td></tr><tr><td> Age</td><td>0.006</td><td>0.010</td><td>1.01 (0.99,1.03)</td><td>0.563</td></tr><tr><td> BMI</td><td>0.027</td><td>0.026</td><td>1.03 (0.98,1.08)</td><td>0.311</td></tr><tr><td> FEV<sub>1</sub>, predicted %</td><td>−0.003</td><td>0.004</td><td>1.00 (0.99,1.01)</td><td>0.555</td></tr><tr><td> Wheezing*</td><td>0.509</td><td>0.228</td><td>1.66 (1.06,2.60)</td><td>0.026</td></tr><tr><td> Theophylline</td><td>0.134</td><td>0.515</td><td>1.14 (0.42,3.14)</td><td>0.794</td></tr><tr><td> Oral steroids</td><td>−0.281</td><td>0.218</td><td>0.76 (0.49,1.16)</td><td>0.197</td></tr><tr><td> Inhaled LABA</td><td>−0.363</td><td>0.486</td><td>0.70 (0.27,1.80)</td><td>0.455</td></tr><tr><td> Inhaled LAMA</td><td>−0.369</td><td>0.245</td><td>0.69 (0.43,1.12)</td><td>0.133</td></tr><tr><td> Inhaled ICS*</td><td>0.412</td><td>0.210</td><td>1.51 (1.00,2.28)</td><td>0.049</td></tr><tr><td> Ischemic heart disease</td><td>0.312</td><td>0.362</td><td>1.37 (0.67,2.77)</td><td>0.389</td></tr><tr><td> Heart failure</td><td>−0.549</td><td>0.537</td><td>0.58 (0.20,1.66)</td><td>0.307</td></tr><tr><td> Hypertension</td><td>0.409</td><td>0.220</td><td>1.50 (0.98,2.32)</td><td>0.063</td></tr><tr><td> Arrhythmia</td><td>0.438</td><td>0.487</td><td>1.55 (0.60,4.03)</td><td>0.368</td></tr><tr><td> Depression</td><td>1.294</td><td>0.797</td><td>3.65 (0.76,17.4)</td><td>0.105</td></tr><tr><td> Anxiety</td><td>−0.124</td><td>0.823</td><td>0.88 (0.18,4.43)</td><td>0.880</td></tr><tr><td> CAT score*</td><td>0.085</td><td>0.017</td><td>1.09 (1.05,1.13)</td><td><0.001</td></tr><tr><td> mMRC score*</td><td>0.264</td><td>0.125</td><td>1.30 (1.02,1.66)</td><td>0.035</td></tr></table> |
600450c2d0bb0a524e589664b8fbc352f7aeab62a989f7c50f59a50791eb1776.png | complex | <table><tr><td colspan="2">Variable</td><td>Number<sup>b</sup></td><td>Percent</td></tr><tr><td rowspan="4">Pregnancy</td><td>1st trimester</td><td>710</td><td>18.40</td></tr><tr><td>2nd trimester</td><td>1344</td><td>34.83</td></tr><tr><td>3rd trimester</td><td>1557</td><td>40.35</td></tr><tr><td>Postpartum 1 m</td><td>248</td><td>6.43</td></tr><tr><td rowspan="3">Age (years)</td><td>≤25</td><td>173</td><td>4.47</td></tr><tr><td>26 ~ 35</td><td>2859</td><td>73.93</td></tr><tr><td>≥36</td><td>835</td><td>21.59</td></tr><tr><td rowspan="2">Employment status</td><td>No</td><td>886</td><td>23.08</td></tr><tr><td>Yes</td><td>2952</td><td>76.92</td></tr><tr><td rowspan="2">Marital status</td><td>Married</td><td>3747</td><td>97.07</td></tr><tr><td>Single and others</td><td>113</td><td>2.93</td></tr><tr><td rowspan="3">Monthly income (NT$)<sup>a</sup></td><td><30,000</td><td>151</td><td>3.94</td></tr><tr><td>30,000 ~ 100,000</td><td>2437</td><td>63.61</td></tr><tr><td>>100,000</td><td>1243</td><td>32.45</td></tr><tr><td rowspan="3">Educational level</td><td><9 years</td><td>886</td><td>1.19</td></tr><tr><td>9 ~ 12 years</td><td>2952</td><td>12.78</td></tr><tr><td>>12 years</td><td>886</td><td>86.03</td></tr><tr><td rowspan="2">Parity</td><td>1</td><td>2194</td><td>59.51</td></tr><tr><td>2+</td><td>1493</td><td>40.49</td></tr></table> |
19168b55ee1c4b4cc04413d6c295d226efe2a9a9daa2e8018188f95bdac27dd7.png | complex | <table><tr><td>Parameters</td><td>Early RRT(<i>n</i> = 58)</td><td>Standard RRT(<i>n</i> = 60)</td><td><i>P</i> value</td></tr><tr><td>Age (years), mean (SD)</td><td>67.5 (15.0)</td><td>66.7 (16.7)</td><td>0.80</td></tr><tr><td>Male, <i>n</i> (%)</td><td>29 (50)</td><td>29 (48.3)</td><td>0.86</td></tr><tr><td>ICU, <i>n</i> (%)</td><td></td><td></td><td>0.79</td></tr><tr><td> Medical</td><td>40 (69)</td><td>40 (66.7)</td><td rowspan="2"></td></tr><tr><td> Surgical</td><td>18 (31)</td><td>20 (33.3)</td></tr><tr><td>Mechanical ventilation, <i>n</i> (%)</td><td>48 (82.8)</td><td>50 (83.3)</td><td>0.93</td></tr><tr><td>Vasopressors, <i>n</i> (%)</td><td>45 (77.6)</td><td>47 (78.3)</td><td>0.92</td></tr><tr><td>Sepsis, <i>n</i> (%)</td><td>37 (63.8)</td><td>32 (53.3)</td><td>0.25</td></tr><tr><td>APACHE II score, mean (SD)</td><td>24.5 (6.4)</td><td>21.8 (6.9)</td><td>0.027</td></tr><tr><td>SOFA score, mean (SD)</td><td>12.7 (3.3)</td><td>11.4 (4.0)</td><td>0.058</td></tr><tr><td>Nonrenal SOFA score, mean (SD)</td><td>9.9 (3.3)</td><td>9.1 (4.1)</td><td>0.21</td></tr><tr><td>Baseline serum creatinine (mg/dL), mean (SD)</td><td>1.14 (0.44)</td><td>1.03 (0.37)</td><td>0.16</td></tr><tr><td>Estimated GFR (mL/min/1.73m<sup>2</sup>), mean (SD)<sup>a</sup></td><td>70.31 (28.1)</td><td>69.98 (22.8)</td><td>0.95</td></tr><tr><td>AKI staging, <i>n</i> (%)</td><td></td><td></td><td>0.06</td></tr><tr><td> 1</td><td>11 (19)</td><td>12 (20)</td><td></td></tr><tr><td> 2</td><td>27 (46.6)</td><td>16 (26.7)</td><td></td></tr><tr><td> 3</td><td>20 (34.5)</td><td>32 (53.3)</td><td></td></tr><tr><td>Blood urea nitrogen at enrollment (mg/dL), median (IQR)</td><td>42 (37–78)</td><td>51 (37.5–61.25)</td><td>0.52</td></tr><tr><td>Serum creatinine at enrollment (mg/dL), median (IQR)</td><td>2 (2–3)</td><td>2.5 (2–3)</td><td>0.88</td></tr><tr><td colspan="4">Co-morbidities, <i>n</i> (%)</td></tr><tr><td> Hypertension</td><td>29 (50)</td><td>24 (56.7)</td><td>0.47</td></tr><tr><td> Diabetes</td><td>14 (24.1)</td><td>15 (25)</td><td>0.91</td></tr><tr><td> Dyslipidemia</td><td>16 (27.6)</td><td>16 (26.7)</td><td>0.91</td></tr><tr><td> Ischemic heart disease</td><td>12 (20.7)</td><td>10 (16.7)</td><td>0.58</td></tr><tr><td> Malignancy</td><td>12 (20.7)</td><td>8 (13.3)</td><td>0.29</td></tr><tr><td> Cerebrovascular disease</td><td>5 (8.6)</td><td>7 (11.7)</td><td>0.58</td></tr><tr><td> Chronic liver disease</td><td>10 (17.2)</td><td>11 (18.3)</td><td>0.88</td></tr><tr><td colspan="4">Nephrotoxic drugs, n (%)</td></tr><tr><td> Colistin</td><td>5 (8.6)</td><td>10 (16.7)</td><td>0.19</td></tr><tr><td> Vancomycin</td><td>1 (1.7)</td><td>1 (1.7)</td><td>0.98</td></tr><tr><td> Contrast</td><td>8 (13.8)</td><td>11 (18.3)</td><td>0.50</td></tr><tr><td> Aminoglycosides</td><td>2 (3.4)</td><td>2 (3.3)</td><td>0.97</td></tr><tr><td> Amphotericin</td><td>2 (3.4)</td><td>0 (0)</td><td>0.15</td></tr><tr><td> NSAIDs</td><td>2 (3.4)</td><td>1 (1.7)</td><td>0.54</td></tr><tr><td>Cardiac surgery, <i>n</i> (%)</td><td>13 (22.4)</td><td>8 (13.3)</td><td>0.20</td></tr><tr><td>Treatment limitation, <i>n</i> (%)<sup>b</sup></td><td>12 (20.7)</td><td>10 (16.7)</td><td>0.58</td></tr><tr><td>Fluid accumulation at randomization (mL), median (IQR)</td><td>4763 (2837–8515)</td><td>5114 (2050–8803)</td><td>0.84</td></tr><tr><td>Percentage of fluid overload, median (IQR)<sup>c</sup></td><td>9.53 (3.43–19.68)</td><td>7.63 (2.10–12.02)</td><td>0.87</td></tr><tr><td>Baseline NGAL (ng/mL), median (IQR)</td><td>625 (376–1362)</td><td>860 (447–1204)</td><td>0.63</td></tr><tr><td>Baseline NT-proBNP (pg/mL), median (IQR)</td><td>4301 (515–35,000)</td><td>5844 (869–10,007)</td><td>0.71</td></tr><tr><td>Baseline angiopoietin-2 (ng/mL), median (IQR)</td><td>16,784 (8649–35,545)</td><td>22,294 (12539–33,186)</td><td>0.95</td></tr></table> |
0dd7c3a02f46a4fe1d0d5ba3f7e22919ac183c7994cdadb86b0d45a8b1f05997.png | simple | <table><tr><td>Kinesthetic variables</td><td>Test session 1 Mean (SD)</td><td>Test session 2 Mean (SD)</td><td>Mean difference (SDdiff), 95% CI</td><td>ICC<sub>2,1</sub>(95% CI)</td><td>95% LOA<sub>ratio</sub></td></tr><tr><td>TE20</td><td>0.98 (0.37)</td><td>1.03 (0.51)</td><td>0.05 (0.35), -0.10 – 0.19</td><td>0.70 (0.42 – 0.86)</td><td>0.57 – 1.78</td></tr><tr><td>TE40</td><td>1.20 (0.52)</td><td>1.26 (0.75)</td><td>-0.06 (0.84), -0.41 – 0.30</td><td>0.16 (-0.27 – 0.53)</td><td>0.31 – 3.09</td></tr><tr><td>TF20</td><td>1.55 (0.66)</td><td>1.29 (0.70)</td><td>-0.26 (0.55), -0.49 – -0.03</td><td>0.63 (0.31 – 0.83)</td><td>0.42 – 1.57</td></tr><tr><td>TF40</td><td>0.79 (0.28)</td><td>0.81 (0.34)</td><td>0.02 (0.28), -0.10 – 0.14</td><td>0.59 (0.25 – 0.80)</td><td>0.51 – 2.01</td></tr></table> |
a44d8315e97a1ddf2aa2a946e99ccef8d7e8927fb0089fb4f8af30328efbf31a.png | simple | <table><tr><td>Parameter</td><td>Exposed</td><td>Controls</td></tr><tr><td>CC16 [pg/mL]</td><td>6.7 (3.7 - 9.0)</td><td>7.2 (5.0 - 8.7)</td></tr><tr><td>IL-6 [pg/mL]</td><td><4.7 (<4.7 - 7.4)</td><td><4.7 (<4.7 - 23.9)</td></tr><tr><td>IL-8 [pg/mL]</td><td>21.7 (11.0 - 38.9)</td><td>16.5 (11.4 - 34.4)</td></tr><tr><td>BPI [pg/mL]</td><td>3201 (<408 - 4741)</td><td>2310 (<408- 4102)</td></tr><tr><td>LBP [μg/mL]</td><td>19.9 (15.8 - 25.2)</td><td>22.0 (15.8 - 29.2)</td></tr><tr><td>sCD14 [μg/mL]</td><td>1.3 (1.0 - 1.8)</td><td>1.2 (1.1 - 2.1)</td></tr></table> |
9b87723c6a7b70525c775473a13be6bb1060f61a39cde6269cf4bca71f784891.png | complex | <table><tr><td rowspan="2">Precursor</td><td colspan="2">Bond length in precursor (Å)</td><td colspan="4">Bond length in transition state structures (Å)</td></tr><tr><td>M-S bond <sup>a</sup></td><td>C-S bond</td><td>M-S bond <sup>a</sup></td><td>C-S bond</td><td>C-N bond</td><td>N-H bond <sup>b</sup></td></tr><tr><td>Ag(SCOPh)</td><td>2.540</td><td>1.820</td><td>2.398</td><td>2.660</td><td>1.603</td><td>1.061</td></tr><tr><td>Cu(SCOPh)</td><td>2.348</td><td>1.812</td><td>2.173</td><td>2.669</td><td>1.601</td><td>1.060</td></tr><tr><td>Cd(SCOPh)<sub>2</sub></td><td>2.632</td><td>1.803</td><td>2.454</td><td>2.801</td><td>1.564</td><td>1.102</td></tr><tr><td>In(SCOPh)<sub>3</sub></td><td>2.725</td><td>1.777</td><td>2.373</td><td>2.608</td><td>1.628</td><td>1.035</td></tr></table> |
fc49a3f39df864c3a9b9ae4a798b2eeef5080224906020ae9b5eec66adbc8227.png | complex | <table><tr><td></td><td><i>Number</i></td><td><i>Incidence (%)</i></td><td><i>Anomalies (%)</i></td></tr><tr><td colspan="4">Benign anomalies</td></tr><tr><td>CA from RCS</td><td>8</td><td>1.07</td><td>24.24</td></tr><tr><td>Absence of LMA</td><td>7</td><td>0.93</td><td>21.21</td></tr><tr><td>Posterior RCA</td><td>1</td><td>0.13</td><td>3.03</td></tr><tr><td colspan="4">Potentially clinically significant anomalies</td></tr><tr><td>Superior RCA</td><td>7</td><td>0.93</td><td>21.21</td></tr><tr><td>CFX from RCS</td><td>4</td><td>0.53</td><td>12.12</td></tr><tr><td>CFX from RCA</td><td>2</td><td>0.26</td><td>6.06</td></tr><tr><td>Coronary fistula</td><td>1</td><td>0.13</td><td>3.03</td></tr><tr><td>Coronary aneurysm</td><td>1</td><td>0.13</td><td>3.03</td></tr></table> |
e40d0d7b60a4f54807a8baa400cb94c5c6c187ba37a98562fa462b015a306db5.png | simple | <table><tr><td>Metric</td><td>Value</td></tr><tr><td>Families making <Q 2000<sup>a</sup> per month</td><td>66 %</td></tr><tr><td>Families making Q 2000–4000<sup>a</sup> per month</td><td>34 %</td></tr><tr><td>Average persons per household</td><td>6.4</td></tr><tr><td>Average children per household</td><td>3.3</td></tr></table> |
7d56d0bf98877c7180c6301713e9c125f513282a5e878188efa6f49866c9203c.png | simple | <table><tr><td></td><td># Samples</td><td># Pairs</td><td># IBD Segments</td><td>Mean/Median/SD # IBD Segments/Pair</td><td>Mean/Median/SD Size (Mb)/Segment</td><td>Mean/Median/SD Size (Mb)/Pair</td></tr><tr><td>NLD</td><td>92</td><td>4186</td><td>4548</td><td>1.09/1/1.05</td><td>3.99/3.57/1.36</td><td>4.34/3.5/4.57</td></tr><tr><td>TWN</td><td>58</td><td>1653</td><td>15444</td><td>9.34/8/6.45</td><td>9.34/7.22/8.20</td><td>87.25/71.99/73.88</td></tr><tr><td><i>p</i>-value</td><td></td><td></td><td></td><td><0.0001</td><td><0.0001</td><td><0.0001</td></tr></table> |
9fd3588efc04293acef8d74b01eeb04d545230a5c0d3a6ad43af095ba1ee7cf2.png | simple | <table><tr><td></td><td>Baseline</td><td>Normal protein</td><td>High protein</td><td>Reference range</td></tr><tr><td>Glucose mg/dL</td><td>83 ± 12</td><td>85 ± 14</td><td>84 ± 19</td><td>65–99</td></tr><tr><td>BUN mg/dL</td><td>22 ± 5</td><td>23 ± 5</td><td>23 ± 6</td><td>7–25</td></tr><tr><td>Creatinine mg/dL</td><td>1.1 ± 0.2</td><td>1.1 ± 0.1</td><td>1.1 ± 0.2</td><td>0.60–1.35</td></tr><tr><td>eGFR ml/min/1.73 m2</td><td>96 ± 20</td><td>102 ± 18</td><td>101 ± 18</td><td>§</td></tr><tr><td>BUN/Creatinine ratio</td><td>19.4 ± 5.4</td><td>21.2 ± 4.5</td><td>20.5 ± 2.8</td><td>6–22</td></tr><tr><td>Sodium mmol/L</td><td>139 ± 2</td><td>138 ± 2</td><td>138 ± 1</td><td>135–146</td></tr><tr><td>Potassium mmol/L</td><td>4.3 ± 0.4</td><td>4.2 ± 0.3</td><td>4.3 ± 0.2</td><td>3.5–5.3</td></tr><tr><td>Chloride mmol/L</td><td>103 ± 2</td><td>102 ± 1</td><td>102 ± 3</td><td>98–110</td></tr><tr><td>Carbon Dioxide mmol/L</td><td>27 ± 2</td><td>27 ± 4</td><td>27 ± 2</td><td>19–30</td></tr><tr><td>Calcium mg/dl</td><td>9.7 ± 0.2</td><td>9.6 ± 0.3</td><td>9.6 ± 0.3</td><td>8.6–10.3</td></tr><tr><td>Total Protein g/dL</td><td>7.2 ± 0.4</td><td>7.2 ± 0.3</td><td>7.1 ± 0.4</td><td>6.1–8.1</td></tr><tr><td>Albumin g/dL</td><td>4.7 ± 0.2</td><td>4.6 ± 0.2</td><td>4.6 ± 0.3</td><td>3.6–5.1</td></tr><tr><td>Globulin g/dL</td><td>2.5 ± 0.3</td><td>2.6 ± 0.3</td><td>2.6 ± 0.3</td><td>1.9–3.7</td></tr><tr><td>Albumin/Globulin ratio</td><td>1.9 ± 0.2</td><td>1.8 ± 0.2</td><td>1.8 ± 0.2</td><td>1.0–2.5</td></tr><tr><td>Total Bilirubin mg/dL</td><td>0.7 ± 0.3</td><td>0.7 ± 0.2</td><td>0.7 ± 0.3</td><td>0.2–1.2</td></tr><tr><td>Alkaline Phosphatase U/L</td><td>65 ± 17</td><td>66 ± 20</td><td>65 ± 16</td><td>40–115</td></tr><tr><td>AST U/L</td><td>28 ± 9</td><td>27 ± 6</td><td>27 ± 6</td><td>10–40</td></tr><tr><td>ALT U/L</td><td>29 ± 19</td><td>27 ± 9</td><td>28 ± 10</td><td>9–46</td></tr></table> |
15d4433ab62eacdd28d4abcaf7847d207579980354953492516720c682d9bc99.png | simple | <table><tr><td></td><td>Study 1</td><td>Study 2</td></tr><tr><td>Age, y</td><td>24 ± 4</td><td>26 ± 3</td></tr><tr><td>Body mass, kg</td><td>72.9 ± 3.9</td><td>65.8 ± 9.0</td></tr><tr><td>Height, m</td><td>1.70 ± 0.09</td><td>1.70 ± 0.10</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>25.0 ± 1.1</td><td>22.8 ± 0.9</td></tr><tr><td>Body fat, kg</td><td>24.2 ± 11.4</td><td>19.3 ± 3.7</td></tr><tr><td>Body fat, %</td><td>32.4 ± 2.0</td><td>29.8 ± 6.5</td></tr><tr><td>Lean mass, kg</td><td>45.3 ± 8.1</td><td>43.6 ± 8.7</td></tr><tr><td>Peak bike power, watts</td><td>n/a</td><td>145 ± 43</td></tr><tr><td>Peak VO<sub>2</sub>, mL/kg/min</td><td>n/a</td><td>26.4 ± 5.9</td></tr><tr><td>Peak heart rate, beats/min</td><td>n/a</td><td>179 ± 15</td></tr><tr><td>Total cholesterol, mmol/L</td><td>3.98 ± 0.99</td><td>4.03 ± 0.90</td></tr><tr><td>HDL cholesterol, mmol/L</td><td>1.21 ± 0.37</td><td>1.11 ± 0.33</td></tr><tr><td>Triglycerides, mmol/L</td><td>0.74 ± 0.39</td><td>0.89 ± 0.31</td></tr><tr><td>C-reactive protein, nmol/L</td><td>18.4 ± 19.9</td><td>11.0 ± 5.2</td></tr><tr><td>Glucose, mmol/L</td><td>4.7 ± 0.2</td><td>4.8 ± 0.5</td></tr><tr><td>Insulin, pmol/L</td><td>41 ± 28</td><td>41 ± 27</td></tr><tr><td>Systolic blood pressure, mmHg</td><td>109 ± 9</td><td>112 ± 10</td></tr><tr><td>Diastolic blood pressure, mmHg</td><td>68 ± 8</td><td>62 ± 7</td></tr></table> |
ec847a1bf6d6cf9081e8446a0aec92255008cad8d54da90ed517438ca295667e.png | complex | <table><tr><td>Compound</td><td>LOD (μg/L)</td><td>LOQ (μg/L)</td><td>RSD (%)</td><td>Recovery (%)</td><td>Method</td><td>References</td></tr><tr><td>Caffeine</td><td>3610</td><td>10,940</td><td>1.7</td><td>95 ± 7</td><td rowspan="3">HPLC–DAD–MS</td><td rowspan="3">[4]</td></tr><tr><td>Theobromine</td><td>30</td><td>100</td><td>6.5</td><td>97 ± 3</td></tr><tr><td>Trigonelline</td><td>3770</td><td>11,420</td><td>1.0</td><td>102 ± 2</td></tr><tr><td>Caffeine</td><td>80</td><td rowspan="3">–</td><td>0.20–6.2</td><td>99 ± 3</td><td rowspan="3">HPLC–UV</td><td rowspan="3">[9]</td></tr><tr><td>Theobromine</td><td>140</td><td>2.8–9.1</td><td>103 ± 6</td></tr><tr><td>Trigonelline</td><td>260</td><td>1.1–5.0</td><td>99 ± 5</td></tr><tr><td>Caffeine</td><td>11.9</td><td>39.6</td><td>2.1–4.7</td><td>97 ± 4</td><td rowspan="3">LC–MS</td><td rowspan="3">[12]</td></tr><tr><td>Theobromine</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Trigonelline</td><td>36.4</td><td>121.5</td><td>3.2–3.5</td><td>140 ± 16</td></tr><tr><td>Caffeine</td><td>2</td><td>40</td><td>3</td><td>99 ± 2</td><td rowspan="3">Fluorescence</td><td rowspan="3">This study</td></tr><tr><td>Theobromine</td><td>6</td><td>20</td><td>3</td><td>–</td></tr><tr><td>Trigonelline</td><td>7</td><td>20</td><td>4</td><td>99 ± 2</td></tr></table> |
6e602fdfcf15def87c85aced6f3f3b0742e38b36a5e793f5c731e9b6d226043e.png | simple | <table><tr><td>Inclusion Criteria</td><td>Exclusion Criteria</td></tr><tr><td>◆ Student at Haskell Indian Nations University◆ Age at least 18 years or older◆ Have a valid college/university email address, telephone number, and home address◆ Willing to participate in all study components◆ Willing to be followed-up over several years (1-4 years, depending on freshman cohort year)</td><td>◆ Planning to leave or graduate from the University before the end of the current academic year◆ Unable to participate in all components of the study</td></tr></table> |
92491a8ce4648c9b351d39c27138cf8aa8c0432f41af8258b745dfc9b8053bdc.png | complex | <table><tr><td>Mean radio-density</td><td colspan="3">Technique</td><td colspan="3">p-values*</td></tr><tr><td>At depth of</td><td>1 (Syringe Spreader)</td><td>2 (Syringe Lentulo Spiral)</td><td>3 (Specially Designed Paste Carrier)</td><td>1 cf 2</td><td>1 cf 3</td><td>2 cf 3</td></tr><tr><td>1 mm</td><td>6.9 (3.2-10.5)</td><td>13.9 (6.6-21.1)</td><td>28.8 (22.6-35.0)</td><td>0.236</td><td>0.001</td><td>0.001</td></tr><tr><td>3 mm</td><td>14.1 (7.1-21.2)</td><td>23.9 (17.6-30.2)</td><td>35.2 (28.9-41.6)</td><td>0.086</td><td>0.001</td><td>0.037</td></tr><tr><td>5 mm</td><td>13.5 (7.1-19.8)</td><td>21.9 (12.7-31.1)</td><td>36.8 (31.3-42.2)</td><td>0.250</td><td>0.001</td><td>0.009</td></tr><tr><td>7 mm</td><td>22.4 (16.7-30.2)</td><td>23.5 (15.5-31.4)</td><td>34.5 (28.5-40.6)</td><td>1.000</td><td>0.047</td><td>0.079</td></tr><tr><td>Overall density</td><td>14.2 (9.9-18.6)</td><td>20.8 (16.0-25.6)</td><td>33.83 (30.2-37.5)</td><td>0.077</td><td>0.001</td><td>0.001</td></tr></table> |
9a110546e390374524a09302363e58e988f834ad9f1d443b25ad1005112ef13d.png | complex | <table><tr><td>Vasectomy technique</td><td>Early recanalization</td><td colspan="3">Vasectomy outcome</td><td>Total</td></tr><tr><td></td><td></td><td>Failure<sup>a </sup>n (%)</td><td>Success<sup>b </sup>n (%)</td><td>Indeterminate<sup>c </sup>n (%)</td><td></td></tr><tr><td>FI trial</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LE</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>46 (87)</td><td>49 (15)</td><td>10 (31)</td><td>105 (25)</td></tr><tr><td></td><td>No</td><td>7 (13)</td><td>282 (85)</td><td>22 (69)</td><td>311 (75)</td></tr><tr><td></td><td>Total</td><td>53 (100)</td><td>331 (100)</td><td>32 (100)</td><td>416 (100)</td></tr><tr><td>LE and FI</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>20 (83)</td><td>20 (6)</td><td>1 (2)</td><td>41 (10)</td></tr><tr><td></td><td>No</td><td>4 (17)</td><td>323 (94)</td><td>42 (98)</td><td>369 (90)</td></tr><tr><td></td><td>Total</td><td>24 (100)</td><td>343 (100)</td><td>43 (100)</td><td>410 (100)</td></tr><tr><td>Cautery study</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>EC</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>2 (100)</td><td>13 (7)</td><td>2 (40)</td><td>17 (9)</td></tr><tr><td></td><td>No</td><td>0 (0)</td><td>177 (93)</td><td>3 (60)</td><td>180 (91)</td></tr><tr><td></td><td>Total</td><td>2 (100)</td><td>190 (100)</td><td>5 (100)</td><td>197 (100)</td></tr><tr><td>TC and FI</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td></td><td>No</td><td>1 (100)</td><td>188 (100)</td><td>3 (100)</td><td>192 (100)</td></tr><tr><td></td><td>Total</td><td>1 (100)</td><td>188 (100)</td><td>3 (100)</td><td>192 (100)</td></tr></table> |
09e9dd23fbfa69e927f664ea343e6904218a7fb4eedf82565ad1b56474360141.png | complex | <table><tr><td rowspan="2">Time interval(months)</td><td colspan="2">Primary endpoint*</td><td rowspan="2">ARR(%)</td><td rowspan="2">RRR[95% CIs] (%)</td><td rowspan="2">NNT(per month)</td></tr><tr><td>Clopidogrel(%)</td><td>Placebo(%)</td></tr><tr><td colspan="6">CURE trial</td></tr><tr><td>0–1</td><td>4.3</td><td>5.5</td><td>1.2</td><td>22 [9, 32]</td><td>84</td></tr><tr><td>1–3</td><td>1.8</td><td>2.5</td><td>0.8</td><td>32 [13, 46]</td><td>240</td></tr><tr><td>3–6</td><td>1.8</td><td>1.8</td><td>0.0</td><td>4 [−27, 27]</td><td>5174</td></tr><tr><td>6–9</td><td>1.3</td><td>1.4</td><td>0.1</td><td>6 [–34, 34]</td><td>3171</td></tr><tr><td>9–12</td><td>1.1</td><td>1.3</td><td>0.2</td><td>14 [−32, 44]</td><td>1600</td></tr><tr><td>0–12</td><td>10.3</td><td>12.6</td><td>2.4</td><td>19</td><td>507</td></tr><tr><td colspan="6">CHARISMA trial</td></tr><tr><td>0–28</td><td>6.8</td><td>7.3</td><td>0.5</td><td>7*</td><td>5591</td></tr><tr><td colspan="6"><i>Subgroup of patients with clinically evident atherosclerotic disease</i></td></tr><tr><td>0–28<sup>‡</sup></td><td>6.9</td><td>7.9</td><td>1.0</td><td>12</td><td>2800</td></tr></table> |
6c9a7f53ad164f057147e20adb01d37215c0fe641497796578237d1d77c5e425.png | complex | <table><tr><td>Nutrient</td><td colspan="2">Unfortified cereal (<i>n</i> = 37)</td><td colspan="2">Fortified cereal (<i>n</i> = 34)</td><td><i>P</i> value<sup>b</sup></td></tr><tr><td></td><td>Pre-intervention</td><td>Post-intervention</td><td>Pre-intervention</td><td>Post-intervention</td><td></td></tr><tr><td></td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td><td></td></tr><tr><td>Vitamin B<sub>1</sub> (mg)</td><td>1.1 (0.40)</td><td>1.3 (0.35)**</td><td>1.2 (0.50)</td><td>2.2 (0.36)**</td><td><0.001</td></tr><tr><td>Vitamin B<sub>2</sub> (mg)</td><td>1.0 (0.41)</td><td>1.4 (0.35)**</td><td>1.2 (0.43)</td><td>2.7 (0.50)**</td><td><0.001</td></tr><tr><td>Niacin (mg)</td><td>25 (8.1)</td><td>27 (9.0)</td><td>27 (11.1)</td><td>41 (10.3)**</td><td><0.001</td></tr><tr><td>Vitamin B<sub>6</sub> (mg)</td><td>1.2 (0.45)</td><td>1.8 (0.40)**</td><td>1.3 (0.53)</td><td>3.0 (0.64)**</td><td><0.001</td></tr><tr><td>Vitamin B<sub>12</sub> (μg)</td><td>3.1 (1.81)</td><td>2.8 (1.09)</td><td>2.8 (1.44)</td><td>4.1 (1.78)**</td><td><0.001</td></tr><tr><td>Folate (μg)</td><td>148 (55)</td><td>151 (61)</td><td>171 (69)</td><td>314 (54)**</td><td><0.001</td></tr><tr><td>Vitamin D (μg)</td><td>1.5 (1.35)</td><td>1.6 (0.91)</td><td>1.8 (1.28)</td><td>5.5 (1.32)**</td><td>0.007</td></tr><tr><td>Calcium (mg)</td><td>677 (282)</td><td>822 (248)**</td><td>713 (282)</td><td>775 (177)</td><td><0.001</td></tr><tr><td>Sodium (mg)</td><td>2419 (7367)</td><td>2528 (631)</td><td>2335 (863)</td><td>2576 (637)</td><td>0.628</td></tr><tr><td>Iron (mg)</td><td>8.3 (2.47)</td><td>7.7 (2.37)</td><td>8.9 (2.86)</td><td>13.1 (2.31)**</td><td><0.001</td></tr></table> |
3dcaa4f13452329176c921c7e03d518386916eec991bc9aa5d29e7c68c42585a.png | complex | <table><tr><td></td><td colspan="3">Group</td></tr><tr><td>Variable</td><td>Dry</td><td>10 kg milk</td><td>20 kg milk</td></tr><tr><td>Diameter of vein (cm)</td><td>0.69 ± 0.13 (0.28 - 1.10)</td><td>0.63 ± 0.09 (0.38 - 0.87)</td><td>0.87 ± 0.15 (0.54 - 1.32)</td></tr><tr><td>Maximum blood flow velocity (cm/s)</td><td>61.78 ± 12.8 (30.0 - 94.9)</td><td>118.08 ± 19.9 (77.6 - 189.5)</td><td>119.13 ± 16.0 (78.8 - 159.8)</td></tr><tr><td>Minimum blood flow velocity (cm/s)</td><td>1.96 ± 0.40 (0.8 - 3.1)</td><td>8.80 ± 2.80 (2.9 - 18.4)</td><td>7.87 ± 1.40 (3.4 - 11.0)</td></tr><tr><td>Mean maximum blood flow velocity (cm/s)</td><td>30.59 ± 5.6 (15.1 - 43.5)</td><td>81.90 ± 16.3* (45.2 - 136.3)</td><td>85.15 ± 12.3*(59.6 - 116.5)</td></tr><tr><td>Blood flow volume (l/min)</td><td>0.52 ± 0.20 (0.0 - 1.5)</td><td>0.70 ± 0.10 (0.5 - 0.9)</td><td>1.57 ± 0.40 (0.8 - 3.1)</td></tr></table> |
e7357b2edb7f94ae15bc7551bbaaab96d752beaf73bc87f9cb4b91a1f7572e01.png | simple | <table><tr><td></td><td>Food-specific decentering</td><td>Awareness of food thoughts</td><td>Meditation experience</td></tr><tr><td>Food cravings</td><td>−0.62<sup>a</sup></td><td>0.27</td><td>−0.47 <sup>a</sup></td></tr><tr><td>Food-specific decentering</td><td></td><td>−0.29</td><td>0.25</td></tr><tr><td>Awareness of food thoughts</td><td></td><td></td><td>−0.20</td></tr></table> |
d520c5b43806eb59366b303dbdf57619b80336b5cad2f870107f96bf31433802.png | simple | <table><tr><td>Value</td><td>Uniform<sup>a</sup></td><td>Uniform</td><td>Uniform</td></tr><tr><td></td><td></td><td>Placental<sup>b</sup></td><td>Peripheral<sup>c</sup></td></tr><tr><td>Sensitivity Histology (Median, CI)</td><td>0.497 (0.414, 0.588)</td><td>0.498 (0.410, 0.589)</td><td>0.504 (0.397, 0.646)</td></tr><tr><td>Sensitivity PCR (Median, CI)</td><td>0.960 (0.862, 0.998)</td><td>0.961 (0.859, 0.998)</td><td>0.953 (0.841, 0.998)</td></tr><tr><td>Specificity Histology (Median, CI)</td><td>0.976 (0.963, 0.987)</td><td>0.972 (0.955, 0.985)</td><td>0.971 (0.951, 0.986)</td></tr><tr><td>Specificity PCR (Median, CI)</td><td>0.991 (0.969, 0.9996)</td><td>0.994 (0.974, 0.9997)</td><td>0.964 (0.906, 0.998)</td></tr><tr><td>Prevalence Mozambique (Median, CI)</td><td>0.368 (0.305, 0.436)</td><td>0.370 (0.301, 0.437)</td><td>0.334 (0.252, 0.412)</td></tr><tr><td>Prevalence Malawi (Median, CI)</td><td>0.0813 (0.056, 0.110)</td><td>0.063 (0.039, 0.094)</td><td>0.094 (0.049, 0.150)</td></tr></table> |
1203bd5de6e6099ac4bfa7c1021a2b9358967a1e39db2ab79aadc903b29aa84b.png | complex | <table><tr><td rowspan="3"><i>Group</i></td><td colspan="9"><i>Frequency (kHz)</i></td></tr><tr><td><i>0.5</i></td><td><i>0.7</i></td><td><i>1.0</i></td><td><i>1.4</i></td><td><i>2.0</i></td><td><i>3.0</i></td><td><i>4.0</i></td><td><i>5.0</i></td><td><i>6.0</i></td></tr><tr><td>With stimuli</td><td>9.2±4.5</td><td>12.5±5.1</td><td>12.1±5.3</td><td>13.4±6.1</td><td>7.9±6.4</td><td>5.5±5.3</td><td>4.9±4.6</td><td>2.9±7.4</td><td>-0.4±7.4</td></tr><tr><td>Without stimuli</td><td>9.7±5.0</td><td>12.0±5.9</td><td>12.4±5.6</td><td>13.6±5.9</td><td>7.7±6.2</td><td>5.6±6.0</td><td>4.4±5.0</td><td>2.9±77</td><td>-0.4±7.8</td></tr><tr><td>P value</td><td>0.452</td><td>0.357</td><td>0.433</td><td>0.627</td><td>0.716</td><td>0.863</td><td>0.310</td><td>0.966</td><td>0.937</td></tr></table> |
543c40df3e9350a9e7faf4410033c7523351fb351d99dc36e27bca111b878337.png | simple | <table><tr><td> Logistic portion of the ZIP model</td><td></td><td></td><td></td></tr><tr><td></td><td><i>Model 4</i></td><td><i>Model 5</i></td><td><i>Model 6</i></td></tr><tr><td>Lifetime Earnings<sup>§</sup></td><td>.55*(.28, .91)</td><td>1.08(.81, 1.42)</td><td>1.10(.80, 1.51)</td></tr><tr><td>Gender</td><td></td><td>1.15(.50, 2.64)</td><td>1.16(.50, 2.71)</td></tr><tr><td>Age</td><td></td><td>.77***(.67, .83)</td><td>.76***(.66, .82)</td></tr><tr><td>Race<i>(white is reference</i>)</td><td></td><td>.35(.08, 1.45)</td><td>.32(.08, 1.37)</td></tr><tr><td>Educational Attainment<i>(less than high school is reference)</i></td><td></td><td></td><td></td></tr><tr><td> High School/GED</td><td></td><td></td><td>2.03(.73, 5.69)</td></tr><tr><td> Some College or more</td><td></td><td></td><td>.84(.27, 2.55)</td></tr><tr><td>Poisson Portion of the ZIP model</td><td></td><td></td><td></td></tr><tr><td></td><td><i>Model 4</i></td><td><i>Model 5</i></td><td><i>Model 6</i></td></tr><tr><td>lifetime earnings<sup>§</sup></td><td>.93***(.91, .95)</td><td>.93***(.91, .95)</td><td>.95***(.93, .98)</td></tr><tr><td>Gender</td><td></td><td>1.14***(1.08, 1.20)</td><td>1.11***(1.05, 1.17)</td></tr><tr><td>Age</td><td></td><td>1.02***(1.02, 1.03)</td><td>1.02***(1.02, 1.03)</td></tr><tr><td>Race<i>(white is reference</i>)</td><td></td><td>1.22(.54, 2.78)</td><td>1.23(.53, 2.83)</td></tr><tr><td>Educational Attainment<i>(less than high school is reference)</i></td><td></td><td></td><td></td></tr><tr><td> High School/GED</td><td></td><td></td><td>.26(.06, 1.06)</td></tr><tr><td> Some College or more</td><td></td><td></td><td>1.76(.63, 4.89)</td></tr></table> |
4e3842a5c332de176d75a7eb0b2265e11791589817fdff80e8c4924f5b1639ac.png | simple | <table><tr><td>MolNo.</td><td>R1</td><td>R2</td><td>Predicted activity</td><td>Lipinski’s scoreandScreen</td></tr><tr><td>R-1</td><td>4-nitrophenyl</td><td>4-methoxyphenyl</td><td>0.8564</td><td>ADRXWS (6)</td></tr><tr><td>R-2</td><td>4-nitrophenyl</td><td>4-nitrophenyl</td><td>-0.3876</td><td>ADRXWS (6)</td></tr><tr><td>R-3</td><td>Benzyl</td><td>4-hydroxyphenyl</td><td>0.9765</td><td>ADRXWS (6)</td></tr><tr><td>R-4</td><td>3-aminophenyl</td><td>4-nitrophenyl</td><td>0.8450</td><td>ADRXWS (6)</td></tr></table> |
4b62e20b343271ddc1ffb4dc1efef5013fab7fcb19e154241bd3233c81482996.png | simple | <table><tr><td>Percent of invaded area</td><td>Himalayan blackberry</td><td>English ivy</td></tr><tr><td>In clusters</td><td>98.5</td><td>99.3</td></tr><tr><td>In outliers</td><td>1.5</td><td>0.7</td></tr></table> |
9fe927fa9f651ac62848eb7e5d90566a1ffc5e6ea488faba361e8ddc0769b7a2.png | complex | <table><tr><td></td><td></td><td colspan="2">MB</td><td colspan="2">no-MB</td></tr><tr><td></td><td></td><td>Pre- training</td><td>Post-training</td><td>Pre- training</td><td>Post-training</td></tr><tr><td>LBD</td><td>Subacute</td><td>63.4 ± 3.1</td><td>61.8 ± 3.1</td><td>63.9 ± 3.1</td><td>64.7 ± 3.1</td></tr><tr><td></td><td>Chronic</td><td>69.2 ± 2.6</td><td>65.5 ± 2.6</td><td>67.4 ± 2.6</td><td>67.8 ± 2.6</td></tr><tr><td>RBD</td><td>Subacute</td><td>70.2 ± 2.4</td><td>68.7 ± 2.4</td><td>67.1 ± 2.4</td><td>68.1 ± 2.4</td></tr><tr><td></td><td>Chronic</td><td>66.4 ± 3.3</td><td>65.4 ± 3.3</td><td>66.8 ± 3.3</td><td>65.1 ± 3.3</td></tr></table> |
161f69d69b8b3cd48711bff14d537cb9dab55ea4cec60db0987eaf6f34e3c1ed.png | simple | <table><tr><td>KDQOL-36TM Subscales</td><td>Mean</td><td>SD</td><td>Minimal (Floor%)</td><td>Maximal (Ceiling%)</td></tr><tr><td>Symptoms/problems list</td><td>74.22</td><td>15.24</td><td>37.50 (1)</td><td>100 (2.9)</td></tr><tr><td>Effects of kidney disease</td><td>54.78</td><td>20.10</td><td>00.00 (1)</td><td>96.88 (1)</td></tr><tr><td>Burden of kidney disease</td><td>33.07</td><td>23.31</td><td>00.00 (13.6)</td><td>100 (1)</td></tr><tr><td>Physical Composite Sore</td><td>36.60</td><td>7.83</td><td>17.05 (1)</td><td>54.92 (1)</td></tr><tr><td>Mental Composite Score</td><td>46.82</td><td>9.81</td><td>22.17 (1)</td><td>65.09 (1)</td></tr></table> |
347a93f7e7906b4626281d92e33a4034712e08922fcf255294b79d23dc1f6425.png | simple | <table><tr><td>VARIABLE/CLUSTER</td><td>CLUSTER 1: "Highest Risk"</td><td>CLUSTER 2: "At Risk"</td><td>CLUSTER 3: "Right Behavior/Wrong Results"</td><td>CLUSTER 4: "Getting Best Results"</td><td>CLUSTER 5: "Doing OK"</td><td>P value<sup>a</sup></td></tr><tr><td><i>Gender </i>(% female)</td><td>53.0</td><td>45.6</td><td>59.8</td><td>72.2</td><td>62.1</td><td>0.008 **</td></tr><tr><td><i>Education </i>(%)</td><td></td><td></td><td></td><td></td><td></td><td>0.000 ***</td></tr><tr><td>Less than high school</td><td>0.0</td><td>3.7</td><td>0.0</td><td>0.0</td><td>0.0</td><td></td></tr><tr><td>High school grad</td><td>2.4</td><td>11.0</td><td>3.6</td><td>11.1</td><td>5.3</td><td></td></tr><tr><td>Some college</td><td>54.8</td><td>58.1</td><td>56.5</td><td>31.5</td><td>49.1</td><td></td></tr><tr><td>Bachelors or more</td><td>42.9</td><td>27.2</td><td>39.9</td><td>57.4</td><td>45.6</td><td></td></tr><tr><td><i>Income </i>(%)</td><td></td><td></td><td></td><td></td><td></td><td>0.000 ***</td></tr><tr><td>Less than $20,000</td><td>17.3</td><td>20.2</td><td>5.6</td><td>7.1</td><td>14.5</td><td></td></tr><tr><td>$20,001 to $35,000</td><td>10.7</td><td>21.1</td><td>16.0</td><td>11.9</td><td>32.7</td><td></td></tr><tr><td>$35,001 to $50,000</td><td>16.0</td><td>18.4</td><td>9.0</td><td>14.3</td><td>16.4</td><td></td></tr><tr><td>$50,001 to $65,000</td><td>16.0</td><td>18.4</td><td>17.4</td><td>9.5</td><td>9.1</td><td></td></tr><tr><td>$65,001 or greater</td><td>40.0</td><td>21.9</td><td>52.1</td><td>57.1</td><td>27.3</td><td></td></tr><tr><td><i>Children </i>(% has children)</td><td>37.3</td><td>45.3</td><td>48.2</td><td>45.5</td><td>32.8</td><td>0.216</td></tr><tr><td><i>Employment </i>(%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Employed</td><td>53.0</td><td>46.0</td><td>43.5</td><td>58.2</td><td>79.3</td><td>0.000 ***</td></tr><tr><td>Unemployed</td><td>2.4</td><td>3.7</td><td>0.6</td><td>3.6</td><td>3.4</td><td>0.417</td></tr><tr><td>Retired</td><td>27.7</td><td>13.2</td><td>13.6</td><td>23.6</td><td>19.0</td><td>0.027 *</td></tr><tr><td><i>Age range </i>(%)</td><td></td><td></td><td></td><td></td><td></td><td>0.000 ***</td></tr><tr><td>16–24</td><td>0.0</td><td>19.0</td><td>9.5</td><td>12.7</td><td>10.2</td><td></td></tr><tr><td>25–34</td><td>15.7</td><td>23.4</td><td>17.9</td><td>16.4</td><td>30.5</td><td></td></tr><tr><td>35–44</td><td>19.3</td><td>23.4</td><td>27.4</td><td>16.4</td><td>10.2</td><td></td></tr><tr><td>45–54</td><td>26.5</td><td>12.4</td><td>21.4</td><td>16.4</td><td>18.6</td><td></td></tr><tr><td>55–64</td><td>12.0</td><td>8.8</td><td>11.9</td><td>12.7</td><td>11.9</td><td></td></tr><tr><td>65 or more</td><td>26.5</td><td>13.1</td><td>11.9</td><td>25.5</td><td>18.6</td><td></td></tr><tr><td><i>Region </i>(%)</td><td></td><td></td><td></td><td></td><td></td><td>0.001 ***</td></tr><tr><td>Northern</td><td>27.7</td><td>28.7</td><td>30.2</td><td>31.5</td><td>19</td><td></td></tr><tr><td>South</td><td>19.3</td><td>27.2</td><td>23.1</td><td>29.6</td><td>46.6</td><td></td></tr><tr><td>Middle America</td><td>16.9</td><td>27.9</td><td>30.2</td><td>20.4</td><td>22.4</td><td></td></tr><tr><td>West</td><td>36.1</td><td>16.2</td><td>16.6</td><td>18.5</td><td>12.1</td><td></td></tr><tr><td><i>Urban characteristic </i>(%)</td><td></td><td></td><td></td><td></td><td></td><td>0.163</td></tr><tr><td>Rural</td><td>30.1</td><td>26.3</td><td>33.9</td><td>23.6</td><td>38.6</td><td></td></tr><tr><td>Suburban</td><td>43.4</td><td>41.4</td><td>45.8</td><td>54.5</td><td>45.6</td><td></td></tr><tr><td>Urban</td><td>26.5</td><td>32.3</td><td>20.2</td><td>21.8</td><td>15.8</td><td></td></tr></table> |
fc47884a6981863692f8f11b8b9020a68ef56a76e935f220c3f1cfaa12576d2c.png | simple | <table><tr><td>Measure</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td></tr><tr><td>1. PCL-F</td><td>--</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2. PCL-F symptom group B</td><td>0.73 ***</td><td>--</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3. PCL-F symptom group C</td><td>0.90 ***</td><td>0.45 ***</td><td>--</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4. PCL-F symptom group D</td><td>0.86 ***</td><td>0.53 ***</td><td>0.65 ***</td><td>--</td><td></td><td></td><td></td><td></td></tr><tr><td>5. CAPS frequency score</td><td>0.72 ***</td><td>0.52 ***</td><td>0.61 ***</td><td>0.65 ***</td><td>--</td><td></td><td></td><td></td></tr><tr><td>6. CAPS frequency symptom group B</td><td>0.33 **</td><td>0.58 ***</td><td>0.11</td><td>0.26 *</td><td>0.62 ***</td><td>--</td><td></td><td></td></tr><tr><td>7. CAPS frequency symptom group C</td><td>0.62 ***</td><td>0.25 *</td><td>0.68 ***</td><td>0.53 ***</td><td>0.86 ***</td><td>0.24 *</td><td>--</td><td></td></tr><tr><td>8. CAPS frequency symptom group D</td><td>0.66 ***</td><td>0.50 ***</td><td>0.49 ***</td><td>0.70 ***</td><td>0.82 ***</td><td>0.40 ***</td><td>0.60 ***</td><td>--</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.